US Pat. No. 10,336,783

SOLID CATALYST FOR HYDRIDE ISOMERIZATION REACTION IN AN AQUEOUS MEDIUM

JAPAN SCIENCE AND TECHNOL...

1. A method for selectively producing fructose as a produced product from glucose as a raw material, the method comprising:conducting a catalytic hydride isomerization reaction from glucose to fructose in the presence of a solid catalyst in water or in an aqueous solution,
obtaining the produced product from the water or the aqueous solution,
wherein the solid catalyst consists essentially of a Group 13 element oxide whose surface is bonded with a phosphoric acid to form a structure of —O—P(O)(OH)2 with the Group 13 element oxide.
US Pat. No. 10,337,040

PROCESS FOR ENZYMATIC HYDROLYSIS OF LIGNOCELLULOSIC MATERIAL AND FERMENTATION OF SUGARS

DSM IP ASSETS B.V., Heer...

1. A process for the preparation of a sugar product from lignocellulosic material, comprising:enzymatic hydrolysis and oxidation of the lignocellulosic material in the presence of an enzyme composition comprising at least two cellulases and a lytic polysaccharide monooxygenase (LPMO);
adding 20-10,000 mmol of oxygen per kg glucan to the lignocellulosic material during the enzymatic hydrolysis;
wherein the enzymatic hydrolysis is conducted until at least 70% of available sugar in the lignocellulosic material is released; and
wherein at the end of the enzymatic hydrolysis the amount of gluconic acid formed during oxidation of the lignocellulosic material is kept between 3 to 10 g/kg glucan present in the lignocellulosic material.
US Pat. No. 10,338,065

DETECTION OF AMNIOTIC FLUID IN VAGINAL SECRETIONS OF PREGNANT WOMEN DUE TO PREMATURE RUPTURE OF FETAL MEMBRANES

Clinical Innovations, LLC...

1. A method for the detection of biomarkers in vaginal secretions of pregnant women indicative of premature rupture of fetal membranes, the method comprising:a) obtaining a fluid sample by placing a sterile swab in a vaginal vault of a pregnant woman;
b) removing the swab from the vaginal vault after a period of time from about fifteen seconds to about three minutes, and placing the swab in a vial containing a buffer solution;
c) allowing time for the fluids from the swab to be released into the buffer solution;
d) adding a few drops of the buffer solution that has been exposed to the fluids from the swab to a chromatographic specific binding assay strip device, the device created by including the following components:
i) a non-permeable platform strip;
ii) a permeable membrane testing strip positioned on top of the non-permeable platform strip, the permeable membrane testing strip further comprising a test site for the detection of the premature rupture of fetal membranes, the site comprising a blend, the blend comprising at least:
1) a first set of polyclonal antibodies for the detection of a first biomarker, the first biomarker indicating the premature rupture of fetal membranes, the first biomarker being alpha-fetoprotein;
2) a second set of polyclonal antibodies for the detection of a second biomarker, the second biomarker being indicative of the premature rupture of fetal membranes, the second biomarker being placental protein 12;
3) a first set of monoclonal antibodies for the detection of the first biomarker being indicative of the premature rupture of fetal membranes, the first set of monoclonal antibodies being specific for alpha-fetoprotein; and
4) a second set of monoclonal antibodies for the detection of a second biomarker, the second biomarker being indicative of the premature rupture of fetal membrane the second set of monoclonal antibodies being specific for placental protein 12;
wherein the ratio of polyclonal antibodies blended together are about 75% placental protein 12 to about 25% alpha-fetoprotein antibodies;
iii) a sample receiving pad positioned on top of and at a proximal end of the non-permeable platform strip while in contact with a proximal end of the permeable membrane testing strip;
iv) a reservoir pad positioned on top of and at a distal end of the non-permeable membrane testing strip while in contact with a distal end of the permeable membrane test strip; and
v) a conjugate pad positioned on top of or below the sample receiving pad, the conjugate pad comprising a permeable membrane containing a conjugate, the conjugate comprising a colorant attached to antibodies that can attach to analytes in the sample, wherein the conjugate of the sample binds to the analytes forming conjugate tagged analytes;
e) allowing time for the conjugate tagged analytes to migrate along the length of the permeable membrane strip to the test site; and
f) detecting binding between the biomarkers and their respective the monoclonal antibodies and the polyclonal antibodies by the presence of an indicator line at the test site.
US Pat. No. 10,337,041

COMPOSITIONS FOR PRODUCING GLUCOSE SYRUPS

1. A composition comprising an alpha-amylase, a pullulanase and a glucoamylase, whereinthe alpha-amylase has at least 90% sequence identity to SEQ ID NO: 5 or a mature polypeptide thereof,
the pullulanase has at least 90% sequence identity to SEQ ID NO: 16 or a mature polypeptide thereof,
the glucoamylase has at least 90% sequence identity to SEQ ID NO: 4 or a mature polypeptide thereof, and
the ratio of pullulanase dose in New Pullulanase Units Novozymes (NPUN)/gDS to alpha-amylase dose in Acid Fungal Alpha-amylase Units (FAU(A))/gDS is at least 60 and the ratio of pullulanase dose in New Pullulanase Units Novozymes (NPUN)/gDS to glucoamylase dose in Glucoamylase Units (AGU)/gDS is in the range of 2-15.
US Pat. No. 10,338,066

MEASUREMENT OF PROTEIN EXPRESSION USING REAGENTS WITH BARCODED OLIGONUCLEOTIDE SEQUENCES

Cellular Research, Inc., ...

1. A method of measuring protein expression in cells, comprising:(a) contacting a plurality of oligonucleotide-conjugated antibodies with a plurality of cells comprising a plurality of protein targets, wherein each of the plurality of oligonucleotide-conjugated antibodies comprises an antibody conjugated with an antibody specific oligonucleotide comprising a unique identifier for the antibody conjugated therewith and a poly(A) tail, and wherein the antibody is capable of specifically binding to at least one of the plurality of protein targets;
(b) partitioning the plurality of cells associated with the plurality of oligonucleotide-conjugated antibodies to a plurality of partitions, wherein a partition of the plurality of partitions comprises a single cell from the plurality of cells associated with the oligonucleotide-conjugated antibodies;
(c) in the partition comprising the single cell, contacting a barcoding particle with the antibody specific oligonucleotides, wherein the barcoding particle comprises a plurality of oligonucleotide probes each comprising a poly(T) region and a barcode sequence selected from a diverse set of unique barcode sequences;
(d) extending the oligonucleotide probes hybridized to the antibody specific oligonucleotides via the hybridization between the poly(A) tails of the antibody specific oligonucleotides and the poly(T) regions of the oligonucleotide probes to produce a plurality of labeled nucleic acids, wherein each of the labeled nucleic acid comprises a unique identifier, or a complementary sequence thereof, and a barcode sequence; and
(e) obtaining sequence information of the plurality of labeled nucleic acids or a portion thereof to determine the quantity of one or more of the plurality of protein targets in one or more of the plurality of cells.
US Pat. No. 10,335,761

METHOD OF MANUFACTURING BIO-DIESEL AND REACTOR

Louisiana Eco Green, L.L....

1. A method of forming bio-diesel comprising:emulsifying a mixture comprising water, alcohol and a source of fatty acids, wherein said alcohol comprises between about 7 and about 16 percent, by weight, of the mixture;
pressurizing and heating said emulsion until said alcohol is super-critical;
pumping said emulsion through a vessel under substantially non-laminar flow;
maintaining said substantially non-laminar flow of said emulsion and said super-criticality of said alcohol in said emulsion for at least about 1.5 minutes.
US Pat. No. 10,336,018

METHOD OF MAKING A GOLF BALL INCORPORATING AT LEAST ONE ELONGATED THERMOSET LAYER

Acushnet Company, Fairha...

1. A method of making a golf ball comprising:providing a subassembly;
providing a thermoset polymer composition;
stepwise elongating the thermoset polymer composition by at least the steps of:
(i) stretching the thermoset polymer composition in at least one plane while the thermoset polymer composition is in a partial cure state and before forming the thermoset polymer composition into first and second half shells; and
(ii) forming the thermoset polymer composition into first and second half shells and elongating the thermoset polymer composition in three dimensions while the thermoset polymer composition is in the partial cure state and before mating the first and second half shells about the subassembly;
mating the first and second half shells about the subassembly and forming a stepwise-elongated thermoset layer.
US Pat. No. 10,336,786

PHARMACEUTICAL TARGETING OF A MAMMALIAN CYCLIC DI-NUCLEOTIDE SIGNALING PATHWAY

Board of Regents, The Uni...

1. A composition comprising an immunogen and an adjuvant, wherein the adjuvant is a cyclic dinucleotide comprising a 5?-monophosphate nucleotide comprising a guanine moiety, and a 5?-monophosphate nucleotide comprising an adenine moiety, wherein the cyclic dinucleotide hasa phosphodiester bond between the 2?-OH of the nucleotide comprising the guanine moiety and the 5?-phosphate of the nucleotide comprising the adenine moiety, and
a phosphodiester bond between the 3?-OH of the nucleotide comprising the adenine moiety and the 5?-phosphate of the nucleotide comprising the guanine moiety.
US Pat. No. 10,337,042

METHOD FOR PRODUCING GALACTOOLIGOSACCHARIDES FROM LACTOSE

Vitalus Nutrition Inc., ...

1. A galactooligosaccharide (GOS) composition comprising:galactose;
glucose;
?-D-Galp-(1?3)-D-Galp;
?-D-Galp-(1?6)-D-Galp;
?-D-Galp-(1?3)-D-Glcp;
?-D-Galp-(1?4)-D-Glcp;
?-D-Galp-(1?6)-?-D-Galp-(1?4)-D-Glcp;
?-D-Galp-(1?2)-D-Glcp;
?-D-Galp-(1?3)-DGlcp;
?-D-Galp-(1?4)-?-D-Galp-(1?4)-D-Glcp;
?-D-Galp-(1?3)-?-D-Galp-(1?4)-D-Glcp;
?-D-Galp-(1?6)-?-D-Galp-(1?6)-?-D-Galp-(1?4)-D-Glcp;
?-D-Galp-(1?6)-?-D-Galp-(1?3)-?-D-Galp-(1?4)-D-Glcp; and
?-D-Galp-(1?6)-?-D-Galp-(1?4)-?-D-Galp-(1?4)-D-Glcp.
US Pat. No. 10,338,067

RAPID ANALYSIS FOR CYANOBACTERIAL TOXINS

Abraxis, Inc., Warminste...

1. A method of releasing a cyanobacterial toxin in a suspension comprising cyanobacteria suspended in an aqueous medium, wherein said method comprises adding a releasing agent to an aliquot of the suspension so as to release toxins from the bacteria into the medium, provided the cyanobacteria are not subjected to a freeze-thaw step before, during, or after the step where the releasing agent is added to the suspension, wherein the releasing agent is a metal salt that comprises a copper atom and which can dissociate in water to release the copper atom as a copper ion, and wherein the releasing agent is selected from the group consisting of copper acetate, copper benzoate, copper bromide, copper chloride, copper chlorate, copper fluoride, copper formate, copper nitrate, copper perchlorate, and copper sulfate.
US Pat. No. 10,337,043

CARBOHYDRATE-ENRICHED RECOMBINANT MICROORGANISMS

CALYSTA, INC., Menlo Par...

1. A recombinant methanotrophic bacterium, comprising an exogenous nucleic acid that encodes a glucan synthase,wherein the recombinant methanotrophic bacterium is capable of producing glucan at a level that is greater than that produced by the parent methanotrophic bacterium; and
wherein the methanotrophic bacterium is selected from the group consisting of Methylomonas, Methylobacter, Methylococcus, Methylosinus, Methylocystis, Methylomicrobium, Methanomonas, and Methylocella.
US Pat. No. 10,335,763

MICROPOROUS CARBON MONOLITHS FROM NATURAL CARBOHYDRATES

Entegris, Inc., Billeric...

1. A carbon pyrolyzate characterized by:derivation from naturally-occurring carbohydrate source material;
<1% total ash content, as determined by the procedure of ASTM D2866-11;
piece density in a range of from 0.50 g/cc to 1.40 g/cc;
N2 BET surface area greater than 750 m2/gm;
having from 40% to 90% of its pore volume in micropores having a size in a range of 0.3 nm to less than 2.0 nm; and
methane adsorption capacity, at 21° C. and 35 bar pressure, of greater than 100V/V.
US Pat. No. 10,336,788

INHIBITION OF CARDIAC FIBROSIS IN MYOCARDIAL INFARCTION

MOERAE MATRIX, INC., Mor...

1. A method for treating ischemia-mediated apoptosis in a peri-infarct border zone in a subject that has suffered a myocardial infarction (MI), the method comprising administering to the subject in need of such treatment a therapeutic amount of a pharmaceutical composition comprising a polypeptide of amino acid sequence YARAAARQARAKALARQLGVAA (SEQ ID NO: 1) or a functional equivalent thereof selected from the group consisting of a polypeptide of amino acid sequence FAKLAARLYRKALARQLGVAA (SEQ ID NO: 4), KAFAKLAARLYRKALARQLGVAA (SEQ ID NO: 5), YARAAARQARAKALARQLAVA (SEQ ID NO: 6), YARAAARQARAKALARQLGVA (SEQ ID NO: 7) and HRRIKAWLKKIKALARQLGVAA (SEQ ID NO: 8); and a pharmaceutically acceptable carrier,wherein
the MI is characterized by aberrant deposition of an extracellular matrix protein, an aberrant promotion of fibroblast proliferation in the heart, an aberrant induction of myofibroblast differentiation, an aberrant promotion of attachment of myofibroblasts to an extracellular matrix or a combination thereof;
wherein when tested in vitro under hypoxic conditions, the pharmaceutical composition is effective to inhibit apoptotic cell death of ventricular cardiomyocyte cells when measured at 16 and 24 hours and atrial cardiomyocyte cells when measured at 12 hours, compared to control cells harvested at initiation of hypoxia challenge;
and
the therapeutic amount of the pharmaceutical composition is effective to inhibit apoptotic cell death of cardiomyocytes in the peri-infarct zone, wherein without the therapeutic effect, ventricular remodeling can progress to heart failure.
US Pat. No. 10,337,044

KANAMYCIN COMPOUND, KANAMYCIN-PRODUCING STREPTOMYCES SPECIES BACTERIUM, AND METHOD OF PRODUCING KANAMYCIN

iNtRON Biotechnology, Inc...

1. A vector for producing 1-N-AHBA-kanamycin comprising a gene set ofkanA, kanB, kanK, kanF, kacA, kanE, kanC, kanD, btrG, btrH, btrI btrJ, btrK, btrO, and btrV.
US Pat. No. 10,338,069

GLYCAN ARRAYS FOR HIGH THROUGHPUT SCREENING OF VIRUSES

ACADEMIA SINICA, Taipei ...

1. A method for detecting at least one influenza serotype in a sample suspected of or comprising one or more viruses, the method comprising the steps of:a) providing a substrate having at least one type of glycan capture probe bound at a discrete location on the substrate, wherein the capture probes can bind to a specific influenza serotype target;
b) providing at least one type of nanoparticle probe conjugated to a detector moiety, wherein the detector moiety binds to the specific influenza serotype;
c) contacting the substrate with the sample suspected of comprising one or more viruses and the nanoparticle probe under conditions suitable for the binding of the glycan capture probes to the specific influenza serotype and the binding of the nanoparticle probe to the specific influenza serotype to form a complex at the discrete location on the substrate; and
d) detecting the presence or absence of the complex wherein the presence or absence of the complex is indicative of the presence or absence of the specific influenza serotype in the sample;
wherein the nanoparticle consists essentially of a noble metal, and
wherein the limit of detection of at least one influenza serotype in said sample suspected of or comprising one or more viruses is less than 104 viral particles.
US Pat. No. 10,336,789

PEPTIDES CAPABLE OF REACTIVATING P53 MUTANTS

Yeda Research and Develop...

1. A recombinant or synthetic peptide comprising an amino-acid sequence selected from the group consisting of SEQ ID NO:319, 320, 316, 318 and 297,wherein said peptide at least partially reactivates a mutant p53 protein; and
wherein said peptide is up to 30 amino-acids in length.
US Pat. No. 10,337,045

METHODS AND MEANS FOR THE PRODUCTION OF IG-LIKE MOLECULES

Merus N.V., Utrecht (NL)...

1. A composition comprising a mixture of at least two different antibodies, wherein one antibody in the mixture comprises a 1st antibody heavy chain comprising at least one substitution of a neutral amino acid residue in the CH3 domain by a positively charged amino acid residue as compared to wildtype, and a 2nd antibody heavy chain comprising at least one substitution of a neutral amino acid residue, as compared to wildtype, in the CH3 domain by a negatively charged amino acid residue, and wherein the positively charged amino acid residue of the first heavy chain interacts with the negatively charged amino acid residue the second heavy chain at the interface between the first and second heavy chains.
US Pat. No. 10,335,509

PRESSURE-SENSITIVE ADHESIVE AGENT FOR SKIN, PRESSURE-SENSITIVE ADHESIVE SHEET FOR SKIN, AND FACE PLATE OF OSTOMY APPLIANCE

ALCARE CO., LTD., Tokyo ...

1. A pressure-sensitive adhesive agent for skin, consisting of:5 to 20% by weight of a hydrogenated styrene-butadiene rubber,
35 to 55% by weight of at least one hydrophilic polymer compound selected from the group consisting of sodium carboxymethyl cellulose, pectin, karaya gum, and gelatin,
a softener component comprising a single softener of 25 to 30% by weight, wherein said single softener is selected from the group consisting of polyisobutylene, polyisoprene, polybutadiene, polybutene, styrene-isoprene rubber, ethylene-propylene rubber, styrene-ethylene-propylene rubber, and derivatives thereof,
0.05 to 3% by weight of a ceramide,
2 to 20% by weight of a mineral oil,
1 to 25% by weight of a tackifying resin comprising a petroleum resin,
and optionally one or more components selected from the group consisting of:
one or more thermoplastic elastomers, one or more hydrophilic polymers,
one or more physiologically active agents selected from the group consisting of sphingolipid, urea, glycolic acid, amino acids and derivatives thereof, protein hydrolysates, mucopolysaccharides and derivatives thereof, a vitamin B group, ascorbic acids, retinoids, vitamin D, vitamin E and derivatives thereof, carotenoids, enzymes, coenzymes, and ?-oryzanol,
one or more oils selected from the group consisting of vegetable oils, animal oils, and synthetic oils,
one or more adhesiveness-imparting resins selected from the group consisting of aliphatic copolymers, aromatic copolymers, aliphatic-aromatic copolymers, alicyclic copolymers, coumarone-indene resins, terpene resins, terpene-phenol resins, rosin resins; (alkyl) phenol resins, xylene resins, and hydrogenated resins thereof, and one or more ingredients selected from the group consisting of powder and pH adjusters.
US Pat. No. 10,337,046

HIGH CONFIDENCE IN POSITIVE STATUS DETERMINATION

BECTON, DICKINSON AND COM...

1. A method comprising:(A) incubating, with an incubator, a culture disposed within a vessel during portions of a time interval between a first time point and a second time point, wherein the culture comprises a sample and a culture media;
(B) measuring, with a sensor, a biological state of the culture at a plurality of time points between the first time point and the second time point, wherein the biological state is one of CO2 concentration, O2 concentration, pH, a rate of change in CO2 concentration, a rate of change in O2 concentration, or a rate of change in pH;
(C) determining, with one or more processors, a plurality of rate transformation values, wherein each rate transformation value is derived from a different subset of the measurements of the biological state of the culture within a predetermined time interval;
(D) determining, with the one or more processors, a plurality of average relative transformation values, wherein each average relative transformation value is derived from a different subset of the rate transformation values;
(E) determining, with the one or more processors, that the culture contains a plurality of microorganisms when (i) at least one average relative transformation value exceeds a first threshold value or (ii) an extent of growth exhibited by the culture exceeds a second threshold value, wherein the extent of growth is derived from one or more of the measurements of the biological state of the culture; and
(F) processing the vessel to confirm the presence of the plurality of microorganisms after it is determined in step (E) that the culture contains a plurality of microorganisms.
US Pat. No. 10,335,766

SUPER ABSORBENT POLYMER AND MANUFACTURING METHOD THEREOF

LG Chem, Ltd., (KR)

1. A super absorbent polymer comprising:super absorbent polymer particles and
silica coated on a surface of the super absorbent polymer particles, wherein
i) a surface area of the silica is 90 to 380 m2/g; and
ii) a content of the silica relative to total weight of the super absorbent polymer particles is 0.05 to 0.3 wt %,
wherein the super absorbent polymer has a gel strength of 5000 Pa to 7500 Pa, a porosity of 25% or more, and a free swell gel bed permeability (FS GBP) of 20 darcy or more.
US Pat. No. 10,336,791

MEANS AND METHODS FOR MEDIATING PROTEIN INTERFERENCE

VIB VZW, Ghent (BE) VRIJ...

1. A non-naturally occurring molecule down-regulating the biological function of a target protein, comprising a beta-aggregation region fused to a moiety,wherein the beta-aggregation region consists of at least 6 contiguous amino acids,
wherein the moiety is a peptide or a protein domain,
wherein the non-naturally occurring molecule has a specificity for the target protein, and
wherein the non-naturally occurring molecule is obtained by the steps comprising:
i) acquiring the amino acid sequence of said target protein;
ii) determining an aggregation propensity score and identifying a beta-aggregation region within the amino acid sequence of said target protein;
iii) isolating the beta-aggregation region from the amino acid encoding sequence of said target protein; and
iv) covalently linking the isolated beta-aggregation region to a moiety to obtain said non-naturally occurring molecule, wherein said peptide or protein domain is not present in the target protein.
US Pat. No. 10,338,072

METHOD OF DETECTING CANCER

Sienna Cancer Diagnostics...

1. A method for detecting bladder cancer epithelial cells comprising:performing a cytological assessment of cells in a fluid sample comprising bladder epithelial cells, wherein said performing detects bladder epithelial cells having atypical cell morphology that is indeterminate of malignancy, wherein the sample is from a subject suspected of having bladder cancer;
contacting the sample with an anti-telomerase antibody; and
detecting binding of the anti-telomerase antibody to the bladder epithelial cells having atypical cell morphology that is indeterminate of malignancy.
US Pat. No. 10,335,511

BIOADHESIVE FOR OCCLUDING VESSELS

Covidien LP, Mansfield, ...

1. A method of treating a vascular malformation of a mammal, the method comprising:injecting a bioadhesive into a vascular malformation of a mammal to displace blood in the malformation and prevent blood flow back into the malformation and to crosslink the bioadhesive in the malformation to form an occlusion in the malformation,
wherein the bioadhesive comprises: (i) a biopolymer having one or more first chemically reactive amine groups; (ii) a biocompatible crosslinker having at least two second chemically reactive groups that can chemically react with the one or more first chemically reactive amine groups of the biopolymer; and (iii) a biocompatible rheological modifier, and
wherein the biopolymer and crosslinker form a crosslinked network and the biocompatible rheological modifier does not substantially react with the biopolymer or the biocompatible crosslinker.
US Pat. No. 10,335,767

SOL-GEL POLYMERIC STATIONARY PHASES FOR HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY AND SOLID PHASE EXTRACTION: THEIR METHOD OF MAKING

THE FLORIDA INTERNATIONAL...

1. A method of preparing a sol-gel sorbent or chromatography stationary phase, comprising:providing a mixture of metal oxide precursors, water and, optionally, a solvent;
providing a polymer comprising at least one hydroxyl group and, optionally, the solvent or a second solvent;
providing an acid catalyst;
mixing the metal oxide precursors, the water, the polymer, the acid catalyst, and, optionally, the solvent and optionally, the second solvent to form a hydrolysis mixture;
providing a basic catalyst and optionally the solvent, the second solvent, or a third solvent;
adding the basic catalyst and optionally the solvent, the second solvent, or a third solvent to the hydrolysis mixture to form a gelation mixture;
optionally, warming the gelation mixture;
holding the gelation mixture until a gel forms; and
crushing or grinding the gel to form particles of a metal oxide gel containing polymeric segments uniformly distributed throughout the metal oxide gel, wherein the particles are a sol-gel sorbent or chromatography stationary phase.
US Pat. No. 10,337,048

METHODS FOR UNIVERSAL DETERMINATION OF ANTICOAGULANT ACTIVITY

Roche Diagnostics Operati...

1. A method for determining an anticoagulant activity elicited by a first anticoagulant in a sample of a subject comprising:(a) measuring a first Factor Xa activity in a body fluid test sample of said subject, said body fluid test sample containing a first anticoagulant;
(b) measuring a second Factor Xa activity in at least one calibrator sample comprising a predefined anticoagulation activity for a second anticoagulant, said second anticoagulant being a chemically different compound than the first anticoagulant; and
(c) calculating a value of a universal parameter for the anticoagulation activity comprised in the test sample based on the first and the second measured Factor Xa activities by (i) allocating a calibration value of said universal parameter to said second measured Factor Xa activity; (ii) comparing the first Factor Xa activity to the second Factor Xa activity; and (iii) from the result of comparing step (ii), deriving said value of the universal parameter for the first Factor Xa activity from said calibration value.
US Pat. No. 10,338,073

LYMPH NODE SPECIMEN COLLECTION KIT AND METHOD OF PATHOLOGICAL ANALYSIS FOR LUNG CANCER DIAGNOSIS USING SUCH A KIT

1. A method of lung cancer diagnosis based upon the consideration of cancerous growth within specific types of lymph nodes in relation to their mediastinal stations, wherein said method comprising the steps of:A) supplying at least one specimen collection kit including twelve separate collection containers provided within at least one enclosure with a lid, wherein each collection container includes a preservative solution and a removable lid, and wherein each collection container is coded in association with a specific station of each and every lymph node to be removed from a subject patients mediastinal region and placed within each suitably coded collection container;
B) removing by a surgeon at least one lymph node from each specifically pre-identified coded mediastinal station of said subject patient, wherein such lymph node removal may be accomplished through any available surgical method;
C) placing by the surgeon each removed lymph node within said preservative solution within its appropriately coded collection container, thereby indicating each different type of removed lymph node present within the collection containers in relation to the actual mediastinal location from which each of said removed lymph nodes was present, and placing the appropriate container lid in sealing fashion on each container after placement of each lymph node therein;
D) providing a pathologist with said at least one specimen collection kit with said properly coded collection containers including the correlated removed lymph nodes in order to permit analysis of each removed lymph node for degree of cancerous growth and/or activity in relation to the mediastinal location of each such lymph node and in relation to any known cancerous growths within the same mediastinal area;
wherein said collection containers of said kit are appropriately coded in terms of target lymph node station through specific colors, numbers, location names, or any combination or combinations thereof;
and wherein said kit includes a checklist for communicating removal of each lymph node and the placement within its appropriately coded collection container and if the placement does not occur said checklist providing a manner of indication any reason said surgeon did not place each lymph node within its appropriately coded collection container to said pathologist; and
E. having the surgeon communicate removal of each lymph node and the placement within its appropriately coded collection container and if the lacement does not occur with the pathologist through the use of the checklist.
US Pat. No. 10,335,512

DERMAL FILLER BASED ON CROSSLINKED HYALURONIC ACID AND CARBOXYMETHYL CELLULOSE LUBRICANT

1. An injectable dermal filler composition in the form of a gel, comprising crosslinked hyaluronic acid and uncrosslinked carboxymethyl cellulose, wherein the crosslinked hyaluronic acid is crosslinked with 1,4-butanediol diglycidyl ether (BDDE), wherein the composition further comprises calcium hydroxyapatite microparticles in a concentration of 20% to 40% volume/volume, and wherein the carboxymethyl cellulose is present at a concentration of 5.0% to 20% volume/volume.
US Pat. No. 10,336,793

FLAGELLIN-BASED AGENTS AND USES INCLUDING EFFECTIVE VACCINATION

GENOME PROTECTION, INC., ...

1. A method of vaccinating a subject against a disorder, comprising administering an effective amount of a vaccine comprising:(a) an adjuvant comprising:
a flagellin-based agent comprising an amino acid sequence having at least 95% identity with SEQ ID NO: 2, and
an aluminum gel or salt,
wherein the ratio (w/w) of flagellin-based agent to aluminum gel or salt is about 1:500 or less and
(b) an antigen which stimulates protective immunity against the disorder,
wherein the antigen is a constituent of an infectious agent selected from a live and attenuated, killed, inactivated, and toxoid infectious agent;
and wherein the disorder is selected from infectious diseases, cancers, and allergies.
US Pat. No. 10,338,074

COMPOSITIONS, METHODS AND KITS FOR DIAGNOSIS OF LUNG CANCER

Biodesix, Inc., Boulder,...

1. A method of determining the likelihood that a pulmonary nodule in a subject is not lung cancer, comprising:(a) contacting a blood sample obtained from the subject with a proteolytic enzyme to produce peptide fragments from a panel of proteins present in the blood sample, wherein the panel comprises LG3BP and C163A;
(b) combining the produced peptide fragments from the panel from step (a) with labeled, synthetic peptide fragments which correspond to the produced peptide fragments from the panel;
(c) performing selected reaction monitoring mass spectrometry to measure the abundance of the peptide fragments from step (b);
(d) calculating a probability of lung cancer score based on the peptide fragment measurements of step (c); and
(e) ruling out lung cancer for the subject if the score in step (d) is lower than a pre-determined score.
US Pat. No. 10,336,794

IMMUNOGENIC BACTERIAL VESICLES WITH OUTER MEMBRANE PROTEINS

GLAXOSMITHKLINE BIOLOGICA...

1. A process for preparing Escherichia bacterial vesicles, comprising the steps of: (i) culturing an Escherichia bacterium in a culture medium such that the bacterium releases vesicles into said medium; and (ii) collecting the vesicles from said medium, wherein: (a) the bacterium has a cell wall that includes peptidoglycan; and (b) the bacterium has a knockout mutation of its mltA gene.
US Pat. No. 10,337,050

POLYPHENOLIC ADDITIVES IN SEQUENCING BY SYNTHESIS

Qiagen Sciences, LLC, Ge...

7. A kit, comprising i) a cleave reagent comprising i) a reducing agent, ii) a polyphenolic compound selected from the group consisting of gallic acid, gentisic acid, pryocatechol, and pyrogallol and iii) a plurality of nucleotide analogues wherein at least a portion of said nucleotide analogues is labeled with a label attached through a cleavable disulfide linker to the base.
US Pat. No. 10,338,075

LUNG CANCER MARKERS AND USES THEREOF

Celera Corporation, San ...

1. A method for detecting an elevated lung cancer biomarker panel, the method comprising detecting the levels of tissue factor pathway inhibitor (TFPI) protein, carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5) protein, Cyfra 21-1 (Cyfra) protein, squamous cell carcinoma antigen (SCC) protein, and osteopontin (OPN) protein in a body fluid sample from a human, detecting said elevated lung cancer biomarker panel when the level of at least one of said proteins is elevated, and administering a therapeutic agent to treat lung cancer to said human when said elevated lung cancer biomarker panel is detected.
US Pat. No. 10,335,514

COMPOSITION, CELL STRUCTURE, PANCREATIC ISLET TRANSPLANTATION KIT, PANCREATIC ISLET CELL TRANSPLANTATION TREATMENT AGENT AND HYPOGLYCEMIC AGENT, COMPOSITION CONTAINING PANCREATIC ISLET, KIT CONTAINING PANCREATIC ISLET, AND PANCREATIC ISLET TRANSPLANTATION

FUJIFILM Corporation, To...

1. A composition comprising:(A): a cell structure which contains a biocompatible macromolecular block and at least one kind of cell and in which a plurality of the macromolecular blocks are arranged in gaps between a plurality of the cells; and
(B): a pancreatic islet,
wherein said biocompatible macromolecular block is a polypeptide, and said at least one kind of cell comprises a mesenchymal stem cell, and said pancreatic islet is an aggregate of a ? cell, a ? cell, a ? cell, a ? cell and a PP cell.
US Pat. No. 10,336,795

SYSTEM AND METHOD FOR PRODUCING PHYCOCYANIN

University of Newcastle, ...

1. A system for producing increased levels of phycocyanin, the system comprising a vessel and a lamp, wherein the lamp provides a source of light, wherein the light consists of electromagnetic radiation consisting of a wavelength of between 670 and 690 nm, and wherein the vessel further comprises a cyanobacteria in a growth medium, and wherein the cyanobacteria synthesizes increased levels of phycocyanin compared to that of cyanobacteria separately cultured in the presence of white light.
US Pat. No. 10,337,051

METHODS AND COMPOSITIONS FOR DETECTING A TARGET RNA

The Regents of the Univer...

1. An acellular in vitro method of detecting a single stranded target RNA in a sample, the method comprising:a) contacting the sample in vitro with:
(i) a C2c2 guide RNA that hybridizes with the single stranded target RNA;
(ii) a first labeled detector RNA comprising at least one uracil;
(iii) a second labeled detector RNA lacking uracil; and
(iv) a C2c2 protein that cleaves the first labeled detector RNA and does not cleave the second labeled detector RNA,
wherein the C2c2 protein comprises an amino acid sequence having 80% or more amino acid sequence identity with the amino acid sequence set forth in SEQ ID NO:2 or SEQ ID NO:6, and
wherein, before said contacting step, the sample comprises a plurality of RNAs that differ from one another in nucleotide sequence; and
b) measuring a detectable signal produced by cleavage of the first labeled detector RNA, wherein said measuring provides for detection of the single-stranded target RNA in the sample.
US Pat. No. 10,338,076

METHODS AND COMPOSITIONS FOR THE DIAGNOSIS OF OVARIAN CANCER

The Wistar Institute of A...

1. A method for diagnosing or detecting or monitoring the progress or treatment of ovarian cancer in a subject comprising:contacting a sample obtained from a test subject with a diagnostic reagent consisting of
(a) a ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 4 (CLIC4) or an isoform, pro-form, modified molecular form, posttranslational modification, or unique peptide fragment or unique nucleic acid fragment thereof;
(b) a ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker chloride intracellular channel protein 1 (CLIC1) or an isoform, pro-form, modified molecular form, posttranslational modification, or unique peptide fragment or unique nucleic acid fragment thereof; and
(c) a ligand capable of specifically complexing with, binding to, or quantitatively detecting or identifying the biomarker cathepsin D-30 (CTSD-30) or an isoform, pro-form, modified molecular form, posttranslational modification, or unique peptide fragment or unique nucleic acid fragment thereof; and
one or more additional ligands, each additional ligand capable of specifically complexing with, binding to, or quantitatively detecting, or identifying an additional biomarker that indicates the presence of ovarian cancer in a human subject, wherein said additional biomarker is selected from:
i. tropomyosin 1 (TPM1);
ii. tropomyosin 2 (TPM2);
iii. tropomyosin 3 (TPM3);
iv. tropomyosin 4 (TPM4);
v. proteasome subunit alpha type-7 (PSMA7)
vi. CA125; and
vii. HE4,
(ii) detecting or measuring in the sample or from a protein level profile generated from the sample, the protein levels of the selected biomarkers;
(iii) comparing the protein level of the selected biomarkers in the subject's sample with the level of the same biomarkers in a reference standard;
wherein a significant change in the protein level of one or more of the selected biomarkers in the subject's sample from that in the reference standard indicates a diagnosis, risk, or the status of progression or remission of ovarian cancer in the subject.
US Pat. No. 10,335,515

HYDROGEL PRECURSORS HAVING NANOPARTICLES

The University of Kansas,...

1. A shape retaining implantable hydrogel precursor composition comprising:a cross-linkable hyaluronic acid polymer having a cross-linkable functional group forming a cross-linkable polymer matrix that is biocompatible;
a photoinitiator; and
a plurality of polymer nanoparticles in the cross-linkable polymer matrix, wherein the polymer nanoparticles are cross-linked hyaluronic acid,
wherein:
the cross-linkable hyaluronic acid polymer is present from about 2% to about 10%;
the polymer nanoparticles are present from about 10% to about 40%; and
the cross-linkable hyaluronic acid polymer matrix having the polymer nanoparticles is a non-flowable gel or paste and has a yield stress in Pa at zero shear rate s?1, wherein:
the cross-linkable functional group is cross-linkable with the photoinitiator, and
the shape retaining implantable hydrogel precursor composition has a shape and shape retention thereof.
US Pat. No. 10,336,796

TREATMENT OF ISCHEMIA

MOREHOUSE SCHOOL OF MEDIC...

1. A method of manufacturing a medicament for treatment of ischemia, comprising:combining an effective amount of an acid sensing ion channel 1a (ASIC1a) inhibitor with a vehicle to produce a medicament for administration to an ischemic subject for treatment of ischemia.
US Pat. No. 10,337,052

METHOD FOR TESTING A MUTANT GENE THROUGH REAL TIME POLYMERASE CHAIN REACTION USING INHIBITION OF 5?-FLAP ENDONUCLEASE ACTIVITY

GENOTECH CORP., Daejeon ...

1. A method of determining a mutation of a gene, the method comprising:providing a template DNA for testing, the template DNA comprising a DNA strand that contains a pre-identified potential SNP location in its sequence;
performing a real-time PCR of the template DNA in the presence of a first primer, a second primer, a DNA polymerase, and a probe to provide a PCR product strand which comprises a primer portion originating from the first primer and a polymerized portion extending from the primer portion, in which the polymerized portion comprises a base at a location corresponding to the pre-identified potential SNP location of the DNA strand,
wherein the probe is configured to enable fluorescence resonance energy transfer (FRET),
wherein the probe comprises a first portion and a second portion that extends from the first portion to a 5?-end of the probe,
wherein the first portion of the probe is designed to be complementary to at least part of the first primer such that the probe hybridizes to the PCR product strand during the real-time PCR,
wherein the second portion of the probe is designed to comprise a first base at the 5?-end of the probe and a second base next to the first base such that the second base corresponds to the base of the PCR product strand at the location corresponding to the pre-identified potential SNP location of the DNA strand and further such that the first base is not complementary to its corresponding base of the PCR product strand,
wherein, when the probe hybridizes to the PCR product strand during the real-time PCR, the first base and the second base of the second portion provide a flap with one base at the 5?-end of the probe if the template DNA does not have a mutation at the pre-identified potential SNP location,
wherein, when the probe hybridizes to the PCR product strand during the real-time PCR, the first base and the second base of the second portion provide a flap with two or more bases at the 5?-end of the probe if the template DNA has a mutation at the pre-identified potential SNP location,
wherein the DNA polymerase has a 5?-flap endonuclease (FEN) activity for a flap with one base while the 5?-flap endonuclease (FEN) activity is inhibited for a flap with two or more bases,
wherein when the probe has a flap with one base, the DNA polymerase hydrolyzes the flap with one base and performs DNA polymerization during the real-time PCR, which will generate a FRET signal,
wherein when the probe has a flap with two or more bases, the 5?-flap endonuclease (FEN) activity of the DNA polymerase is inhibited and does not perform DNA polymerization during the real-time PCR, which does not generate a FRET signal,
determining that the template DNA does not have a mutation at the pre-identified potential SNP location if a FRET signal is detected; and
determining that the template DNA does have a mutation at the pre-identified potential SNP location if a FRET signal is not detected.
US Pat. No. 10,338,077

METHODS FOR DETERMINING DRUG EFFICACY FOR TREATMENT OF CANCER RATION OF CEREBLON ASSOCIATED PROTEINS

CELGENE CORPORATION, Sum...

1. A method of treating a cancer with lenalidomide in a subject, comprising:(a) obtaining a sample from the subject;
(b) measuring mRNA level of cereblon (CRBN);
(c) measuring mRNA level of IKZF1;
(d) determining the ratio of the mRNA level of CRBN to the mRNA level of IKZF1; and
(e) diagnosing the subject as being likely to be responsive to lenalidomide if the ratio of the mRNA level of CRBN to the mRNA level of IKZF1 is higher than 3;
(f) administering lenalidomide to the subject diagnosed as being likely to be responsive to lenalidomide,
wherein the cancer is an Adult T-cell Leukemia (ATL).
US Pat. No. 10,335,516

BIOACTIVE POROUS BONE GRAFT IMPLANTS

PROSIDYAN, INC., New Pro...

1. A porous, composite bone graft implant, comprising:at least one cluster comprising a matrix of randomly oriented bioactive glass fibers and bioactive glass particulates comprising microspheres distributed throughout the bioactive glass fibers, at least some of the fibers and particulates being sintered together, and a bioactive shell comprising bioactive glass at least partially encasing, and at least partially sintered to, the matrix; wherein the fibers, particulates and shell each have a different resorption rate.
US Pat. No. 10,335,772

CATALYST COMPRISING GOLD HOMOGENEOUSLY DISPERSED IN A POROUS SUPPORT

IFP Energies Nouvelles, ...

1. A process for the preparation of a catalyst wherein the catalyst comprises particles of gold and a porous support containing at least one refractory oxide, in which a content of the particles of gold is in the range of 0.01% to 5% by weight with respect to the total weight of the catalyst, and in which the particles of gold are distributed homogeneously through said porous support and have a dimension, measured by transmission electron microscopy, in the range of 0.5 to 5 nm wherein said process comprising the following steps:a) preparing an aqueous solution containing a precursor of the particles of gold;
b) impregnating the porous support containing the at least one refractory oxide with said solution obtained in step a)
c) maturing the impregnated porous support obtained in step b) in order to obtain a catalyst precursor;
d) bringing the catalyst precursor obtained in step c) into contact with a solution containing urea;
e) drying the catalyst precursor obtained in step d) at a temperature in the range of 70° C. to 300° C. to obtain the catalyst.
US Pat. No. 10,336,797

RECOMBINANT FILAGGRIN POLYPEPTIDES FOR CELL IMPORTATION

Research Development Foun...

1. A recombinant polypeptide comprising (a) a filaggrin amino acid sequence; and (b) a cell importation signal sequence comprising a motif of two to fifteen amino acids, wherein the motif comprises at least one arginine residue and at least one methionine residue, wherein the polypeptide comprises SEQ ID NO:21 or SEQ ID NO:22.
US Pat. No. 10,337,053

LABELING HYDROXYMETHYLATED RESIDUES

THE UNTTED STATES OF AMER...

1. A method comprising:(a) labeling covalently, a hydroxyl group on a hydroxymethylated residue in a mammalian nucleic acid to generate a labeled 5-hydroxymethylcytosine residue, wherein said labeling comprises glycosylating the hydroxyl group by employing an alpha-glucosyltransferase, a beta-glucosyltransferase, or a beta-glucosyl-alpha-glucosyl-transferase; and
(b) sequencing said mammalian nucleic acid comprising said labeled hydroxymethylated residue.
US Pat. No. 10,335,517

POROUS POLYMER MATERIAL, PREPARATION METHOD THEREFOR, AND BIOMATERIAL USING SAME

Dankook University Cheona...

1. A porous polymer material having a porous structure over a surface and an inside of the polymer material,wherein the porous structure includes a plurality of first pores formed over the surface of the polymer material, a plurality of second pores in the form of column pores and formed up to a certain distance from the surface of the polymer material, and a plurality of third pores connected to each other and disposed under the plurality of second pores,
wherein the porous polymer material may be in the form of particles, and an average particle size of the particles is 10 to 3000 ?m.
US Pat. No. 10,335,773

FE-BASED HYDROGENATION CATALYST AND USE THEREOF

1. A Fe-based hydrogenation catalyst, consisting of:Fe as a primary active metal component;
zinc and potassium as a first co-active metal component, and
a second co-active element component selected from titanium, zirconium, phosphorus, vanadium, cobalt, nickel, palladium and platinum,
wherein, based on the total weight of the Fe-based hydrogenation catalyst, a total amount of the primary active metal component and co-active element components is 5-100%, with the balance being a binder or carrier, in terms of oxides, and wherein the co-active element components comprise the first co-active metal component and the second co-active element component,
wherein the primary active metal component to the first co-active metal component has a molar ratio that is 0.5-200:1,
wherein the molar ratio of the primary active metal component to the second co-active element component is 0.5-200:1.
US Pat. No. 10,336,798

GROWTH DIFFERENTIATION FACTOR 15 (GDF-15) POLYPEPTIDES

1. A fusion protein comprising:(a) a GDF15 polypeptide comprising an amino acid sequence that is at least 95 percent identical to SEQ ID NO: 4, 8, 12, or 14; and
(b) a negatively charged Fc sequence comprising a lysine-to-aspartate mutation.
US Pat. No. 10,336,799

FIBROBLAST GROWTH FACTOR MUTEINS WITH INCREASED ACTIVITY

Miltenyi Biotec GmbH, Be...

1. A fibroblast growth factor-two (FGF-2) polypeptide that differs from the wild-type FGF-2 (SEQ ID NO:1) at least at amino acid positions 56, 102 and 119, wherein the differences are Q56I, N102G and K119N substitutions, and wherein said FGF-2 polypeptide has a higher thermostability, higher biological activity and higher resistance to proteolytic degradation than wild-type FGF-2.
US Pat. No. 10,338,080

METHODS AND COMPOSITIONS FOR DETECTION OF COMPLEMENT FIXING ANTIBODIES

The Board of Trustees of ...

1. A method for determining the presence or absence of complement fixing antibodies in a biological sample from a subject that bind specifically to human leukocyte antigens (HLAs), the method comprising:incubating a biological sample from a subject with a collection of microparticles of different subtypes and exogenous complement factor C1q, wherein each microparticle is coated with a different purified HLA subtype and wherein the incubating is for a sufficient time to allow anti-HLA complement fixing antibodies in the biological sample to bind to the HLAs and to allow the exogenous complement factor C1q to bind the anti-HLA complement fixing antibodies in the biological sample;
prior to performing any washing step, incubating the microparticles with at least one detectably labeled ligand that specifically binds directly to the exogenous complement factor C1q bound to the anti-HLA complement fixing antibodies bound to the HLAs; and
detecting the presence or absence of the detectably labeled ligand bound to the exogenous complement factor C1q to determine the presence or absence of complement fixing antibodies.
US Pat. No. 10,336,800

THERAPEUTIC USE OF BONE MORPHOGENETIC PROTEINS

CAMBRIDGE ENTERPRISE LIMI...

1. A vector comprising a nucleotide sequence encoding a bone morphogenetic protein 9 (BMP9) variant having endothelial cell signaling activity and lacking osteogenic activity, wherein the difference between the amino acid sequence of said BMP9 variant and the amino acid sequence of SEQ ID NO: 4 consists of a substitution selected from the group consisting of F362A, D366A, I375A, L379A, S402A, D408A, Y416A and Y418A.
US Pat. No. 10,337,056

DYNAMIC FLUX NUCLEIC ACID SEQUENCE AMPLIFICATION

1. A real-time dynamic flux method of nucleic acid sequence amplification, comprising:a. combining a pair of forward and reverse oligonucleotide primers with a target nucleic acid sequence to be amplified; and
b. amplifying the target nucleic acid sequence by thermocycling the pair of forward and reverse oligonucleotide primers and the target nucleic acid sequence within a 15° C. temperature range defined by the melting temperature of the oligonucleotide primers and the melting temperature of the target nucleic acid sequence, and
wherein thermocycling comprises:
i. denaturing the target nucleic acid sequence; and
ii. annealing of the forward and reverse oligonucleotide primers; and
iii. extension of the target nucleic acid sequence by the forward and reverse oligonucleotide primers,
c. simultaneously detecting the amplified target nucleic acid sequence during said amplifying step.
US Pat. No. 10,338,081

TYPE 2 DIABETES BIOMARKERS AND USES THEREOF

Caprion Biosciences Inc.,...

1. A method for monitoring the effectiveness of a diabetic treatment in a subject having type 2 diabetes, the method comprisingdetermining the level of carboxypeptidase M (CPM), insulin-1 (INS), matrilysin (MMP7), and low-density lipoprotein receptor (LDLR) in a first fluid sample(s) obtained from the subject prior to the initiation of the treatment,
wherein the determining of the level of CPM, INS, MMP7, and LDLR in the first fluid sample(s) is performed using mass spectrometry or immunoassay;
determining the level of CPM, INS, MMP7, and LDLR in a second fluid sample(s) obtained from the subject after the treatment has been administered,
wherein the determining of the level of CPM, INS, MMP7, and LDLR in the second fluid sample(s) is performed using mass spectrometry or immunoassay; and
comparing the level of CPM, INS, MMP7, and LDLR in the first sample(s) with a level of CPM, INS, MMP7, and LDLR in the second sample(s), wherein a lower level of CPM, INS, and MMP7, and a higher level of LDLR in the second sample(s) as compared to the level of CPM, INS, MMP7, and LDLR in the first sample(s) indicates that the subject is responding to the diabetic treatment, thereby monitoring the effectiveness of the treatment in the subject.
US Pat. No. 10,336,033

RELEASE FILMS

Airtech International, In...

1. A release film comprising:a first outer layer having a first adhesion affinity and comprising a first base polymer comprising an ethylene tetrafluoroethylene (ETFE); and
a second outer layer having a second adhesion affinity that is different from the first adhesion affinity of the first outer layer, the second outer layer comprising:
a second base polymer comprising an ethylene tetrafluoroethylene (ETFE), and
an adhesion adjusting additive comprising a polyvinylidene fluoride (PVDF) or an ethylene tetrafluoroethylene (ETFE) additive that is different from the second base polymer.
US Pat. No. 10,336,801

CHEMOKINE-CYTOKINE FUSION PROTEINS OF SDF-1 AND CD40L

NATIONAL CHUNG HSING UNIV...

1. A fusion protein, comprising:a chemokine polypeptide, wherein the chemokine polypeptide is stromal cell-derived factor-1; and
a cytokine polypeptide connected to the chemokine polypeptide by a peptide linker,
wherein the peptide linker is a hydrophilic helical peptide linker,
wherein the cytokine polypeptide is CD40 ligand, and
wherein the fusion protein has an amino acid sequence selected from the group consisting of SEQ ID NOs: 46 and 48.
US Pat. No. 10,338,082

METHODS FOR IN VITRO INVESTIGATING MITOCHONDRIAL REPLICATION DYSFUNCTION IN A BIOLOGICAL SAMPLE, KITS AND USES THEREOF, THERAPEUTIC METHODS AGAINST PROGEROID-LIKE SYNDROMES OR SYMPTOMES AND SCREENING METHOD FOR IDENTIFYING PARTICULAR PROTEASE INHIBITOR(S)

INSTITUT PASTEUR, Paris ...

1. An in vitro method to detect a protein in a sample from a subject suspected of having Cockayne syndrome (CS), comprising:a) providing at least one sample from a subject suspected of having CS; and
b) detecting in said sample at least one protein selected from the group consisting of: POLG1, POLG2, HTRA3, and HTRA2.
US Pat. No. 10,335,777

ZSM-5 CATALYST

BASF Corporation, Florha...

1. ZSM-5 zeolite microspheres formed by 1) shaping a mixture into microspheres wherein the mixture comprises a silica material and a plurality of particulates selected from the group consisting of at least one high-density material with an absolute bulk density of at least 0.3 g/cc, ZSM-5 zeolite crystals, and combinations thereof; 2) calcining the microspheres; and 3) reacting and subsequently heating the microspheres with at least one alkali solution to form ZSM-5 zeolite in-situ on the microspheres, wherein the ZSM-5 zeolite microspheres contain substantially no clay or calcined clay material.
US Pat. No. 10,336,802

ACYLATED GLUCAGON ANALOGUE

1. A compound having the formula:R1-H-Aib-QGTFTSDYSKYLDERAAKDFIEWLE-K([17-Carboxy-heptadecanoyl]-isoGlu-GSGSGG)-A-R2  (SEQ ID NO: 1)whereinR1 is H (hydrogen), C1-4 alkyl, acetyl, formyl, benzoyl or trifluoroacetyl; and
R2 is OH or NH2;or a pharmaceutically acceptable salt thereof.
US Pat. No. 10,338,083

PATHWAY SPECIFIC MARKERS FOR DIAGNOSING IRRITABLE BOWEL SYNDROME

NESTEC S.A., Vevey (CH)

1. A method for determining irritable bowel syndrome (IBS) in a subject from a microbiome score and treating the subject in need thereof, the method comprising:(a) detecting in a sample from said subject a panel of markers comprising one or more antibodies against a bacterial antigen selected from the group consisting of Ec0Flic, CjFlaB, SfFliC, EcEra, EcGabT, RbCpaF, PrOmpA and combinations thereof;
(b) calculating a microbiome score based upon the presence or level of said panel of markers using a statistical algorithm to determine if the subject has IBS; and
(c) administering to the subject having IBS a therapeutic drug to treat IBS.
US Pat. No. 10,335,778

CATALYST FOR PRODUCING GAMMA-VALEROLACTONE, METHOD FOR PREPARING THE SAME AND METHOD FOR MANUFACTURING GAMMA-VALEROLACTONE USING THE SAME

KOREA INSTITUTE OF SCIENC...

1. A catalyst for producing gamma-valerolactone, comprising Beta zeolite substituted with a metal; anda heteropolyacid supported on the zeolite.
US Pat. No. 10,336,803

INSULIN SECRETING POLYPEPTIDES

Mayo Foundation for Medic...

1. A method for inducing insulin secretion or treating diabetes, wherein said method comprises administering a composition comprising a polypeptide consisting of the sequence set forth in SEQ ID NO:11 to a mammal.
US Pat. No. 10,338,084

PROCESSING REAGENT AND USE THEREOF IN ASSAYS FOR DETECTION OF ANALYTES ASSOCIATED WITH A BINDING PROTEIN

Quidel Corporation, San ...

1. A method to process and assay a sample, comprising:providing a sample suspected of comprising vitamin D or a metabolite of vitamin D each bound to a binding protein;
contacting the sample with a processing reagent comprising between about 0.2 M to about 0.45 M metaperiodate at a ratio of between about 1:2 and 1:12 to form a mixture;
exposing the mixture to a catalyst that is heat or a manganese salt; and
assaying the mixture by performing an immunoassay comprising contacting an aliquot of the mixture with an antibody that specifically binds vitamin D or vitamin D metabolite to detect vitamin D or vitamin D metabolite in the sample, wherein exposing the mixture to a catalyst that is heat comprises incubating the mixture at a temperature above 25° C. and less than 90° C.
US Pat. No. 10,336,036

CEMENTITIOUS ARTICLE COMPRISING HYDROPHOBIC FINISH

United States Gypsum Comp...

1. A mat-faced gypsum board comprising:(a) gypsum-based core;
(b) fibrous mat having (i) an inner surface in direct contact with at least one face of the gypsum-based core and (ii) an opposite outer surface; and
(c) a continuous hydrophobic finish in direct contact with the outer surface of the fibrous mat, the hydrophobic finish prepared from a wet hydrophobic finish composition comprising:
(i) Class C fly ash, wherein the Class C fly ash is in an amount from about 50% to about 85% by weight of the wet hydrophobic finish composition,
(ii) film-forming polymer, wherein the film-forming polymer is in an amount from about 5% to about 25% by weight of the wet hydrophobic finish composition, and
(iii) silane compound of the general chemical formula:
(RO)3—Si—X,
where RO is an alkoxy group and X is an organofunctional group,
wherein the wet hydrophobic finish composition has a pH of at least about 9, and wherein the wet hydrophobic finish composition is substantially free of any other hydraulic material other than the Class C fly ash,
wherein the film-forming polymer is selected from the group consisting of acrylic polymers and copolymers formed from methyl acrylate, methyl methacrylate, ethyl acrylate, ethyl methacrylate, butyl acrylate, butyl methacrylate, propyl acrylate, propyl methylacrylate, 2-ethyl hexyl acrylate and methacrylate, cyclohexyl acrylate and methacrylate, decyl-acrylate and methacrylate, isodecylacrylate and methacrylate, benzyl acrylate and methacrylate, copolymers of styrene and acrylic, copolymers of vinyl acetate and VeoVa (vinyl ester of versatic acid), copolymers of vinyl laurate and ethylene, terpolymers of vinyl acetate, ethylene and methylmethacrylate, terpolymers of vinyl acetate, ethylene and vinyl laurate, terpolymers of vinyl acetate, ethylene and VeoVa (vinyl ester of versatic acid), and any combination thereof,wherein the board passes the test for waterproofness according to ANSI A118.10 (revised October 2008).
US Pat. No. 10,336,804

CHIMERIC NK RECEPTOR AND METHODS FOR TREATING CANCER

TRUSTEES OF DARTMOUTH COL...

1. A nucleic acid construct comprising: a first nucleic acid sequence encoding a promoter operably linked to a second nucleic acid sequence encoding a chimeric receptor polypeptide, said second nucleic acid sequence comprising a nucleic acid encoding a C-type lectin-like type II natural killer cell receptor polypeptide fused to a nucleic acid encoding an immune signaling receptor polypeptide comprising SEQ ID NO:1, wherein when the nucleic acid construct is introduced into a T-lymphocyte, said chimeric receptor polypeptide is expressed on the surface of the T-lymphocyte, and said C-type lectin type II natural killer receptor polypeptide binds a ligand and activates said immune signaling receptor polypeptide comprising SEQ ID NO: 1.
US Pat. No. 10,337,060

METHOD FOR CHARACTERISING A DOUBLE STRANDED NUCLEIC ACID USING A NANO-PORE AND ANCHOR MOLECULES AT BOTH ENDS OF SAID NUCLEIC ACID

Oxford Nanopore Technolog...

1. A method of characterising a target double stranded polynucleotide using a transmembrane pore in a membrane, comprising:a) providing the target double stranded polynucleotide with a Y adaptor at one end and a hairpin loop adaptor at the other end, wherein the Y adaptor comprises one or more first anchors for coupling the polynucleotide to the membrane, wherein the hairpin loop adaptor comprises one or more second anchors for coupling the polynucleotide to the membrane and wherein the strength of coupling of the hairpin loop adaptor to the membrane is greater than the strength of coupling of the Y adaptor to the membrane;
b) contacting the polynucleotide provided in step a) with the transmembrane pore such that at least one strand of the polynucleotide moves through the pore; and
c) taking one or more measurements as the at least one strand of the polynucleotide moves with respect to the pore wherein the measurements are indicative of one or more characteristics of the at least one strand of the polynucleotide and thereby characterising the double stranded target polynucleotide.
US Pat. No. 10,336,805

CONSUMABLE CRYOPRESERVED CELLS TRANSIENTLY OVEREXPRESSING GENE(S) ENCODING DRUG TRANSPORTER PROTEIN(S) AND/OR DRUG METABOLIZING ENZYME(S)

Corning Incorporated, Co...

1. A recombinant cell comprising one or more transiently overexpressed genes encoding a drug transporter protein, wherein:the recombinant cell is cryopreserved,
activity of the drug transporter protein is detectable in a population of the recombinant cells prior to cryopreservation,
activity of the drug transporter protein is detectable in a population of the recombinant cells following thaw from cryopreservation;
wherein the cryopreserved recombinant cell is transiently transfected with the one or more genes by a method comprising electroporation; and
wherein said one or more genes is MATE2K and wherein said cell is HEK293.
US Pat. No. 10,337,061

METHODS AND SYSTEMS FOR PROCESSING POLYNUCLEOTIDES

10X GENOMICS, INC., Plea...

1. A method for nucleic acid sequencing, comprising:(a) co-partitioning a plurality of beads and a plurality of primers in a plurality of droplets, wherein a droplet of said plurality of droplets comprises (i) a ribonucleic acid (RNA) molecule comprising a nucleic acid sequence, (ii) a primer from said plurality of primers, and (iii) a bead from said plurality of beads, wherein said bead comprises a nucleic acid barcode molecule coupled thereto, and wherein said nucleic acid barcode molecule comprises a barcode sequence;
(b) hybridizing said primer to a region at a 3? end of said RNA molecule;
(c) using an enzyme to extend said primer to generate a nucleic acid product comprising a sequence corresponding to said nucleic acid sequence of said RNA molecule, wherein said enzyme incorporates an end sequence at a 3? end of said nucleic acid product that is complementary to said nucleic acid barcode molecule;
(d) hybridizing said nucleic acid barcode molecule to said nucleic acid product generated in (c) and extending said nucleic acid product using said nucleic acid barcode molecule as a template, to generate a barcoded nucleic acid molecule comprising, from a 5? end to a 3? end, (1) said sequence corresponding to said nucleic acid sequence of said RNA molecule and (2) a complement of said barcode sequence; and
(e) sequencing said barcoded nucleic acid molecule or derivative thereof,
wherein, after (a), said nucleic acid barcode molecule is released from said bead.
US Pat. No. 10,336,038

FIRE RESISTANT COATINGS FOR WOOD VENEER PANELS

Chase Corporation, Westw...

1. A method for treating panels comprising:coating a wood substrate with a polymeric solution comprising urethane acrylate; and
curing the coated wood substrate by subjecting the coated wood to a source of ultraviolet radiation and causing the polymeric solution to crosslink to produce a fire-resistant veneer, the ultraviolet radiation comprising a UV C dose between about 0.15 and about 0.6 J/cm2, a UV V dose between about 0.75 and about 3.5 J/cm2, a UV C irradiance between about 0.15 and about 0.24 W/cm2 and a UV V irradiance between about 0.7 and about 1.3 W/cm2.
US Pat. No. 10,336,806

CONSUMABLE CRYOPRESERVED CELLS TRANSIENTLY OVEREXPRESSING GENE(S) ENCODING DRUG TRANSPORTER PROTEIN(S) AND/OR DRUG METABOLIZING ENZYME(S)

Corning Incorporated, Co...

1. A cryopreserved recombinant cell comprising one or more transiently overexpressed genes encoding a drug transporter protein, wherein activity of the drug transporter protein is detectable in a population of the cryopreserved recombinant cells following thaw from cryopreservation, wherein the cryopreserved recombinant cell is transiently transfected with the one or more genes by a method comprising electroporation, and wherein said one or more genes is MATE2K and wherein said cell is HEK293.
US Pat. No. 10,337,062

TRANSPOSITION OF NATIVE CHROMATIN FOR PERSONAL EPIGENOMICS

The Board of Trustees of ...

1. A method for determining accessibility of a site of a polynucleotide to an insertional enzyme complex, comprising:(a) contacting said polynucleotide with an insertional enzyme complex to produce at least one tagged fragment of said polynucleotide;
(b) performing a nucleic acid assay on said at least one tagged fragment or a derivative thereof to provide insertion data; and
(c) analyzing said insertion data to determine accessibility of said site of said polynucleotide to said insertional enzyme complex.
US Pat. No. 10,336,039

RESIN-COMPATIBLE LAMINATE STRUCTURES

EI DU PONT DE NEMOURS AND...

1. A laminate structure suitable for use as electrical insulation, comprising:a) a first paper layer comprising 90 to 99 weight percent uniformly distributed calcined mica and 1 to 10 weight percent supporting material, a majority by weight of the supporting material being in the form of an aramid floc, the supporting material further comprising a binder that is an aramid fibrid; and
b) a support layer comprising unidirectional filaments or unidirectional yarns or woven yarns, the support layer having a first and second face;
wherein the first face of the support layer is directly bound to a face of the first paper layer;
the laminate structure having a dielectric strength of 15 kV/mm or greater, a Gurley porosity of 400 seconds or less, and a total mica content of 60 weight percent or greater,
wherein the floc in the first paper layer is present in an amount of 60 weight percent or greater, based on the total amount of the supporting material in the first paper layer.
US Pat. No. 10,336,807

CHIMERIC PROTEINS AND METHODS OF IMMUNOTHERAPY

The Board of Trustees of ...

1. A method of inducing death of a target cell, comprising:(a) expressing a system in a lymphocyte; and
(b) contacting said target cell with the lymphocyte under conditions that induce said death of the target cell,
wherein the system expressed in the lymphocyte comprises:
(i) a chimeric transmembrane receptor polypeptide (receptor) comprising a ligand binding domain, an immune cell signaling domain, and a gene modulating polypeptide (GMP), wherein the GMP comprises an actuator moiety linked to a cleavage recognition site, wherein the actuator moiety modulates expression and/or activity of an immune regulatory protein of the lymphocyte, and wherein the immune regulatory protein enhances lymphocyte cytotoxicity and/or reduces a side effect of lymphocyte activation; and
(ii) a chimeric adaptor polypeptide (adaptor) comprising a receptor binding moiety linked to a cleavage moiety, wherein the cleavage moiety is capable of cleaving the cleavage recognition site on the receptor when the receptor binding moiety of the adaptor binds the immune cell signaling domain of the receptor in response to binding of the ligand binding domain of the receptor to a ligand present on the target cell, and wherein the adaptor does not bind a ligand present on the target cell;
wherein the receptor is activatable upon binding to the ligand present on the target cell to recruit the adaptor to the receptor in the lymphocyte, and wherein the recruited adaptor releases the actuator moiety from the GMP of the receptor by action of the cleavage moiety at the cleavage site, thereby inducing death of the target cell.
US Pat. No. 10,337,063

METHODS FOR ANALYZING NUCLEIC ACIDS FROM SINGLE CELLS

10X GENOMICS, INC., Plea...

1. An array for multiplexed nucleic acid analysis, comprising:a solid support having a plurality of beads disposed thereon, wherein the beads are covalently attached to a plurality of oligonucleotide tags, and wherein an oligonucleotide tag of said plurality of oligonucleotide tags comprises:
(a) a first tag sequence configured to distinguish a sample polynucleotide originating from a cell from sample polynucleotides originating from other cells; and
(b) a second tag sequence configured to distinguish said sample polynucleotide from other sample polynucleotide from the same cell and having the same sequence as said sample polynucleotide.
US Pat. No. 10,336,040

METHOD FOR MANUFACTURING A COMPOSITE ELEMENT FOR VACUUM INSULATION ELEMENTS

BASF SE, Ludwigshafen (D...

1. A method for manufacturing a composite element comprising a single- or multi-part core and an envelope which are in a force fit combination with each other, the method comprising:at least partly enveloping a single- or multi-part core of an evacuable organic material with an envelope to obtain a composite element precursor, wherein an envelope surface apposing the core comprises a thermoplastic material;
treating the composite element precursor for a period leading to an at least partial softening of the evacuable organic material and of the envelope surface apposing the core.
US Pat. No. 10,336,808

MHC PEPTIDE COMPLEXES AND USES THEREOF IN INFECTIOUS DISEASES

1. An isolated MHC multimer comprising (a-b-P)n,wherein n>1,
wherein a and b together form a functional MHC protein which is bound to the peptide P,
wherein (a-b-P) is the MHC peptide complex formed when the peptide P is bound to the functional MHC protein,
wherein each MHC peptide complex of the MHC multimer is associated with one or more multimerization domains selected from the group consisting of scaffolds, carriers, optionally substituted organic molecules, membranes, liposomes or micelles, polymers, polysaccharides, dextran moieties, IgG domains, coiled-coil polypeptide structures, DNA duplexes, nucleic acid duplexes, PNA-PNA, PNA-DNA, DNA-RNA, avidins, streptavidins, antibodies, small organic molecules, proteins, a solid support, and biological polymers, with the proviso that the one or more multimerization domains is not a cell,
wherein each MHC protein is an MHC class I molecule encoded by an HLA-A*02 allele, and
wherein in at least one MHC peptide complex, the sequence of P originates from a Borrelia OspC antigen, is capable of binding said MHC class I molecule encoded by an HLA-A*02 allele, and is selected from the group consisting of SEQ ID NOS:49735, 49739, 49779, 49795, 49921, and 49937.
US Pat. No. 10,337,064

METHOD FOR SCREENING AGENTS PROMOTING SKIN BARRIER FUNCTION AND METHOD FOR EVALUATING SKIN BARRIER FUNCTION TAKING EPIDERMAL SERINE RACEMASE AND/OR D-SERINE LEVEL AS INDICATOR

SHISEIDO COMPANY, LTD., ...

1. A method for evaluating a skin barrier function comprising:measuring in a skin sample isolated from a subject an expression level of serine racemase; and
determining the skin barrier function of the subject from the measured expression level of serine racemase.
US Pat. No. 10,336,041

COEXTRUDED MULTILAYER FILM WITH PROPYLENE-BASED POLYMER AND ETHYLENE-BASED POLYMER

Dow Global Technologies L...

1. A coextruded multilayer film comprising:a core component comprising from 15 to 1000 alternating layers of layer A and layer B;
layer A comprising a propylene homopolymer having a density from 0.85 g/cc to 0.95 g/cc and a thickness from 30 nm to 1000 nm and a crystallization temperature (Tpc);
layer B comprising a high density polyethylene (HDPE) having a density of at least 0.94 g/cc and a crystallization temperature (TEc), wherein Tpc is from 115° C. to less than 118° C.; TEc is from greater than 118° C. to 120° C.; and
wherein Tpc layer A has an effective moisture permeability less than 0.40 g-mil/100in2day.
US Pat. No. 10,336,809

PEPTIDES AND COMBINATION OF PEPTIDES FOR USE IN IMMUNOTHERAPY AGAINST VARIOUS TUMORS

IMMATICS BIOTECHNOLOGIES ...

1. A pharmaceutical composition comprising a peptide consisting of the amino acid sequence SEQ ID NO: 14 in the form of a pharmaceutically acceptable salt; and an immunogenicity enhancing amount of at least one adjuvant.
US Pat. No. 10,337,065

TRNA QUANTIFICATION

THE ROCKEFELLER UNIVERSIT...

1. A method for creating a tRNA profile of a cell, said method comprising:a) removing RNA from said cell,
b) hybridizing said RNA with a plurality of DNA probes specific for a portion of tRNA to form DNA/tRNA hybrids, wherein two DNA probes collectively hybridize to the full length of the tRNA, and wherein said probes each hybridize to at least one ribonucleotide of the anticodon of said tRNA,
c) ligating the DNA of said hybrids,
d) digesting the tRNA from said ligated hybrids to form ligated DNA,
e) sequencing said ligated DNA to obtain sequences that correlate to the tRNA present in the cell, and
f) analyzing said sequences to identify the amount of each tRNA in said cell.
US Pat. No. 10,336,810

CHIMERIC ANTIGEN RECEPTORS, ENCODING NUCLEIC ACIDS AND METHODS OF USE THEREOF

University Health Network...

1. A chimeric antigen receptor (CAR) comprising i) an extracellular domain capable of binding to a predetermined antigen, ii) a transmembrane domain and iii) an intracellular segment comprising a) one or more intracellular signaling domains selected from a cytoplasmic domain of an interleukin receptor chain and a cytoplasmic co-stimulatory domain and b) a CD3? intracellular signaling domain comprising an exogenous Signal Transducer and Activator of Transcription (STAT) 3 association motif, wherein the intracellular segment comprises an endogenous or exogenous JAK-binding motif and a STAT5 association motif.
US Pat. No. 10,337,066

METHODS FOR PCR AND HLA TYPING USING UNPURIFIED SAMPLES

Genomics USA, Inc., Roun...

1. A method for amplifying one or more RNAs of interest, comprising:obtaining a sample from an individual;
performing a first reverse transcription reaction on said sample to produce a first cDNA product(s);
diluting the first cDNA product(s) as template into a first PCR reaction; and
performing PCR thereon until all primers are consumed to produce amplicon(s), thereby amplifying the RNA(s) of interest;
wherein the first amplicon(s) are one or more of an HLA-A, an HLA-B or an HLA-DRB1, an HLA-DQA1, or an HLA-DQB1 cDNA(s) and the exon specific primers have a sequence shown in SEQ ID NOS: 15-27.
US Pat. No. 10,336,811

MEMBRANE SPAN-KINASE FUSION PROTEIN AND THE USES THEREOF

VIB VZW, Ghent (BE) Univ...

1. A recombinant protein complex comprising:a first fusion protein consisting of a membrane spanning domain fused to a tyrosine kinase domain, wherein the tyrosine kinase domain has at least 95% sequence identity to amino acids 589-1187 of SEQ ID NO: 1, and
a second fusion protein consisting of an interaction domain fused to a reporter phosphorylation domain, wherein the phosphorylation domain has the amino acid sequence of SEQ ID NO: 2, and
wherein the tyrosine kinase domain can phosphorylate the tyrosine of the reporter phosphorylation domain upon the formation of a recombinant protein complex via an interaction between the membrane spanning domain and the interaction domain.
US Pat. No. 10,337,067

COMPOSITIONS AND METHODS FOR DETERMINING LIKELIHOOD OF TWINNING

Wisconsin Alumni Research...

1. A method for identifying and breeding a member of a bovine population with a decreased likelihood of twinning, comprising the steps of:a) extracting a deoxyribonucleic acid (DNA) sample from a member of the bovine population;
b) detecting, in the DNA sample, the presence of an A allele at nucleotide position 64270644 on bovine chromosome 5 (BTA5), wherein the detecting comprises a laboratory analysis or a field test which utilizes allele-specific polymerase chain reaction (PCR), a nucleic acid probe that specifically binds to the allele, or single-base primer extension;
c) identifying said member of the bovine population as a member of the bovine population with decreased likelihood of twinning; and
d) breeding said member of the bovine population with another bovine animal.
US Pat. No. 10,336,812

GDF15 FUSION PROTEINS AND USES THEREOF

Janssen Biotech, Inc., H...

1. A fusion protein comprising:a. the amino acid sequence of SEQ ID NO: 2;
b. a linker having a length of 35-48 amino acids and comprising the amino acid sequence of (GGGGS)n, wherein n is 7 or 8 (SEQ ID NO: 42 or 43); and
c. a truncated GDF15 consisting of the amino acid sequence of SEQ ID NO: 8;
wherein the fusion protein is arranged from N-terminus to C-terminus in the order (a)-(b)-(c), and the C-terminus of the amino acid sequence of SEQ ID NO: 2 is fused to the N-terminus of the truncated GDF15 through the linker.
US Pat. No. 10,337,068

TRPC6 INVOLVED IN GLOMERULONEPHRITIS

DUKE UNIVERSITY, Durham,...

1. A method of detecting a mutation in a human Transient Receptor Potential Cation Channel, Subfamily C, Member 6 (TRPC6) gene in a sample from a human individual, comprising:(a) contacting a sample comprising a TRPC6 polynucleotide from a human with an oligonucleotide probe, wherein the probe specifically binds to a portion of the nucleotide sequence of SEQ ID NO: 64 including position 762 of the nucleotide sequence of SEQ ID NO: 64, and wherein the probe is detectably labeled with a moiety selected from the group consisting of: enzymatic, radioactive, fluorescent, and luminescent moieties;
(b) hybridizing the probe to the TRPC6 polynucleotide; and
(c) detecting hybridization of the probe to the TRPC6 polynucleotide, wherein hybridization is indicative of the presence of a mutation in the TRPC6 gene in the sample.
US Pat. No. 10,336,045

MATTE FINISH POLYIMIDE FILMS AND METHODS RELATING THERETO

E I DU PONT DE NEMOURS AN...

1. A base film comprising:A. a chemically converted polyimide present in an amount from 75 to 96 weight percent of the base film, the chemically converted polyimide being derived from:
a. 100 mole percent pyromellitic dianhydride, based upon a total dianhydride content of the chemically converted polyimide;
b. 20-80 mole percent 4,4?-oxydianiline based upon a total diamine content of the chemically converted polyimide; and
c. 80-20 mole percent p-phenylenediamine based upon the total diamine content of the chemically converted polyimide;
B. a low conductivity carbon black present in an amount from 2 to 9 weight percent of the base film; and
C. a particulate polyimide matting agent present in an amount from 1.6 to 9 weight percent of the base film and having a median particle size from 1.3 to 10 microns.
US Pat. No. 10,336,813

FUSION PROTEIN SLIT2D2-HSA AND ITS USE IN TREATMENT OF SEPSIS

ASCLEPIUS (SUZHOU) TECHNO...

1. A fusion protein Slit2D2-HSA formed by the fusion of a D2 domain of Slit2 protein and a HSA protein;wherein said D2 domain of Slit2 comprises:
a) an amino acid sequence shown by SEQ ID NO: 1, or
b) an amino acid sequence with a same function obtained by substitution and/or deletion and/or addition of one or more amino acid residues of the aforesaid sequence a);
said HSA comprises:
c) an amino acid sequence shown by SEQ ID NO: 2, or
d) an amino acid sequence with a same function obtained by substitution and/or deletion and/or addition of one or more amino acid residues of the aforesaid sequence c);
wherein the C-terminal domain of said D2 domain of Slit2 is directly linked to the N-terminal domain of said HSA protein, or the N-terminal domain of said D2 domain of Slit2 is directly linked to the C-terminal domain of said HSA protein; and wherein up to 10 amino acid residues are changed for substitution and/or deletion and/or addition.
US Pat. No. 10,337,069

METHOD FOR DIAGNOSING HEPATIC FIBROSIS

VAIOMER, Labege (FR)

1. A method for diagnosing and treating a subject suffering from obesity for a treatment regimen targeting liver fibrosis and/or complications from liver fibrosis, said method comprisinga1) measuring the concentration of bacterial 16S rDNA, or the ratio of the quantity of bacterial 16S rDNA to the quantity of total DNA in a biological sample of a subject;
b) diagnosing liver fibrosis in the subject suffering from obesity based on the result of the measurement in a1); and
c) administering a drug treatment targeting liver fibrosis and/or complications from liver fibrosis to the subject.
US Pat. No. 10,336,814

METHOD FOR OBTAINING THIN FIBRIL COLLAGEN BY CONTACTING NATIVE COLLAGEN WITH AN ANTIBODY

MATRIX ODYSSEY, LLC, Nor...

1. A fibril collagen:wherein the fibril collagen is obtained by providing isolated collagen fibers, wherein the collagen fibers comprise native type II collagen fibers; and
treating the collagen fibers with an antibody to obtain the thin collagen fibrils, wherein the antibody comprises an anti-biglycan antibody and the thin collagen fibrils have a diameter of about 11.5 to about 12.5 nanometers.
US Pat. No. 10,337,070

METHODS AND KITS FOR TREATING CARDIOVASCULAR DISEASE

CardioForecast Ltd., Lon...

1. A method of treating a human subject at risk of a future cardiac event comprising:(a) obtaining information regarding the human subject's single nucleotide polymorphism (SNP) alleles for each of the rs16944 polymorphic locus, the rs1143623 polymorphic locus, the rs4848306 polymorphic locus, the rs17561 polymorphic locus, and the rs1143634 polymorphic locus;
(b) determining that the subject has a positive IL-1 genotype pattern when the IL-1 genotype pattern obtained in (a) matches an IL-1 genotype pattern that is selected from the group consisting of:
(i) T/T or T/G at rs17561, C/C, T/T, C/T or T/C at rs4848306, G/G at rs1143623, C/C at rs16944 and T/T or T/C at rs1143634;
(ii) G/G at rs17561, C/C, T/T, C/T or T/C at rs4848306, G/G at rs1143623, C/C at rs16944 and C/C, T/T, C/T or T/C at rs1143634;
(iii) G/G, T/T, G/T or T/G at rs17561, C/C, T/T, C/T or T/C at rs4848306, G/G at rs1143623, C/C at rs16944 and C/C at rs1143634;
(iv) T/T or T/G at rs17561, C/C or C/T at rs4848306, G/G at rs1143623, C/T at rs16944 and T/T or T/C at rs1143634;
(v) G/G at rs17561, C/C or C/T at rs4848306, G/G at rs1143623, C/T at rs16944 and C/C, T/T, C/T or T/C at rs1143634;
(vi) G/G, T/T, G/T or T/G at rs17561, C/C or C/T at rs4848306, G/G at rs1143623, C/T at rs16944 and C/C at rs1143634;
(vii) T/T or T/G at rs17561, C/C at rs4848306, C/G at rs1143623, C/T at rs16944 and T/T or T/C at rs1143634; 2
(viii) G/G at rs17561, C/C at rs4848306, C/G at rs1143623, C/T at rs16944 and C/C, T/T, C/T or T/C at rs1143634;
(ix) G/G, T/T, G/T or T/G at rs17561, C/C at rs4848306, C/G at rs1143623, C/T at rs16944 and C/C at rs1143634;
(x) T/T or T/G at rs17561, C/C at rs4848306, G/G at rs1143623, T/T at rs16944 and T/T or T/C at rs1143634;
(xi) G/G at rs17561, C/C at rs4848306, G/G at rs1143623, T/T at rs16944 and C/C, T/T, C/T or T/C at rs1143634; and
(xii) G/G, T/T, G/T or T/G at rs17561, C/C at rs4848306, G/G at rs1143623, T/T at rs16944 and C/C at rs1143634;
(c) determining at least one of:
(i) a plasma concentration of LDL-C; and/or
(ii) a plasma concentration of Lp(a)in a sample obtained from the subject;(d) diagnosing the subject as at risk of a cardiac event when the subject has a positive IL-1 pattern determined in step (b) and
(i) a total LDL-C plasma concentration of at least 50 mg/dL, and/or
(ii) a total Lp(a) plasma concentration of at least 5 mg/dL; and
(e) administering canakinumab to the diagnosed subject, thereby reducing the probability of a cardiac event in the subject.
US Pat. No. 10,339,377

DEVICE AND METHOD FOR DETERMINING CHARACTERISTICS OF A CURRENCY NOTE

Kabushiki Kaisha Toshiba,...

1. A method for determining one or more characteristics of a currency note, comprising:receiving, by a currency evaluating device, an image of a currency note;
detecting, by the currency evaluating device, text from one or more predefined first regions of the image;
identifying, by the currency evaluating device, language associated with the detected text;
obtaining, by the currency evaluating device, one of a single nationality or a plurality of nationalities associated with the language of the currency note from a data source associated with the currency evaluating device;
identifying, by the currency evaluating device, nationality of the currency note as said single nationality, when the single nationality is obtained;
identifying, by the currency evaluating device, nationality of the currency note from the plurality of nationalities using Optical Character Recognition (OCR), when the plurality of nationalities is obtained; and
determining, by the currency evaluating device, the one or more characteristics of the currency note by extracting object features of the image based on the identified nationality.
US Pat. No. 10,336,816

PHAGE-DISPLAYED SINGLE-CHAIN VARIABLE FRAGMENT LIBRARY

Academia Sinica, Taipei ...

1. A phage-displayed single-chain variable fragment (scFv) library comprising a plurality of phage-displayed scFvs, wherein each of the plurality of phage-displayed scFvs comprises a first heavy chain complementarity determining region (CDR-H1), a second heavy chain CDR (CDR-H2), a third heavy chain CDR (CDR-H3), a first light chain CDR (CDR-L1), a second light chain CDR (CDR-L2), and a third light chain CDR (CDR-L3),wherein,
each of the CDR-H1, CDR-L2 and CDR-L3 has a type 1 canonical structure (CS), whereas each of the CDR-H2 and CDR-L1 has a type 2 CS; and
each of the CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 has a distribution of aromatic residues that is similar to the distribution of aromatic residues in the corresponding CDR-H1, CDR-H2, CDR-H3, CDR-L1, CDR-L2, and CDR-L3 of a natural antibody; wherein
the CDR-L1 is encoded by a first coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 2-10, the CDR-L2 is encoded by a second coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 11-14, the CDR-L3 is encoded by a third coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 15-22, the CDR-H1 is encoded by a fourth coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 23-26, the CDR-H2 is encoded by a fifth coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 27-28, and the CDR-H3 is encoded by a sixth coding sequence comprising the nucleic acid sequence of any of SEQ ID NOs: 29-106.
US Pat. No. 10,337,072

COPY NUMBER DETECTION AND METHODS

The Board of Trustees of ...

1. A method of determining copy number of a variable copy number version of a replicated target nucleic acid sequence in a sample from a plant, comprising:contacting a sample comprising single-stranded genomic nucleic acids with:
(1) a pair of oligonucleotide primers that anneal upstream and downstream, respectively, of a sequence within the both the defined copy number version and the variable copy number versions of replicated target nucleic acid sequence;
(2) a first non-extendable oligonucleotide probe, with a first 5? fluorescent reporter label and an internal or 3? quencher dye, which first probe anneals specifically to the defined copy number version of the replicated target sequence between the pair of oligonucleotide primers; and
(3) a second non-extendable oligonucleotide probe, with a second 5? fluorescent reporter label and an internal or 3? quencher dye, which second probe anneals specifically to the variable copy number version of the replicated target sequence between the pair of oligonucleotide primers to produce a mixture,wherein the defined copy number version and the variable copy number versions of the target nucleic acid are in the same genome and wherein the defined copy number version of the replicated target nucleic acid sequence is a homeolog of the variable copy number version;maintaining the mixture with a template-dependent nucleic acid polymerase having a 5? to 3? nuclease activity under conditions sufficient to permit the 5? to 3? nuclease activity of the polymerase to cleave the annealed probes and release labeled fragments;
measuring the release of nucleic acid fragments containing fluorescent report label; and
determining the relative amount of released first and second fluorescent reporter fragments, thereby determining copy number of the variable copy number version of the replicated target nucleic acid sequence.
US Pat. No. 10,336,817

THERAPEUTIC COMPOSITION OF CAMEL MILK

Sultan Qaboos University,...

1. A method of making a therapeutic composition of camel milk, comprising the steps of:immunizing a camel against HIV with DNA encoding HIV antigens to provide an HIV-immunized camel, the immunizing comprising 6 immunization treatments, each immunization treatment including administering about 10 mg of DNA encoding HIV antigens to the camel;
preparing an herbal extract comprising the steps of preparing a powdered mixture of the solid material of Saussurea acrophila Diels, Saussurea ceratocarpa, and Aucklandia lappa Decne, soaking the powdered mixture in a first solvent to provide a solvent/powder mixture, incubating the powder/mixture at room temperature, filtering the powder/mixture after incubation to provide a first filtrate and a first retentate, allowing the first solvent to evaporate from the first filtrate, and combining the first filtrate with a second solvent to provide a re-extraction mixture, filtering the re-extraction mixture to provide an extract solution and a second retentate, and allowing the second solvent to evaporate from the extract solution to provide the herbal extract, the herbal extract comprising about 14% extract of Saussurea acrophila Diels, about 14% extract of Saussurea ceratocarpa, and about 72% extract of Aucklandia lappa Decne;
intubating the HIV-immunized camel with the herbal extract in an amount of 500 g to 800 g of the herbal extract per day; and
then collecting an HIV-immunized camel milk from the immunized camel intubated with the herbal extract, the HIV-immunized camel milk including anti-HIV heavy chain IgG antibodies, the HIV-immunized camel milk providing the therapeutic composition.
US Pat. No. 10,337,073

MICRORNA POLYMORPHISMS CONFERRING ENHANCED DROUGHT TOLERANCE IN A PLANT

Syngenta Participations A...

1. A method of producing a maize plant using marker-assisted breeding, wherein said maize plant exhibits increased grain yield at standard moisture percentage, the method comprising the steps of:(a) crossing a first maize plant or a progeny thereof with a second maize plant, wherein said first maize plant or progeny thereof has been selected for said crossing based on the presence of
(a1) at least one polymorphism within a marker locus of its genome, wherein said marker locus is associated with increased grain yield at standard moisture percentage and wherein said marker locus is SEQ ID NO: 84 and
(a2) at least one single nucleotide polymorphism located at a nucleotide corresponding to a position selected from the group consisting of:
(i) position 444 of SEQ ID NO: 69, wherein the nucleotide is a C, and
(ii) position 500 of SEQ ID NO: 69, wherein the nucleotide is a C;
(b) producing a progeny plant population from the cross of (a);
(c) selecting a progeny plant from the progeny plant population of (b) based on genotyping the progeny plant's genomic DNA and selecting a progeny plant having the at least one polymorphism of (a1) and the at least one polymorphism of (a2) said marker locus; and
(d) producing a maize plant using marker-assisted breeding wherein said maize plant exhibits increased grain yield at standard moisture percentage.
US Pat. No. 10,336,818

FC VARIANTS WITH ALTERED BINDING TO FCRN

Xencor, Inc., Monrovia, ...

1. A method of producing a polypeptide comprising a variant Fc region as compared to a parent Fc region, said variant Fc region comprising amino acid substitutions M428L/N434S wherein numbering is according to the EU Index in Kabat et al., said method comprising providing a cell comprising a nucleic acid encoding said polypeptide, wherein said cell is cultured under conditions suitable for expression of said polypeptide.
US Pat. No. 10,336,819

ANTI-TAU ANTIBODIES AND METHODS OF USE

Genentech, Inc., South S...

1. A method of treating a Tau protein associated disease comprising administering to an individual with the Tau protein associated disease a monoclonal antibody that binds to human Tau, wherein the antibody comprises:a) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 342; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 343; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 344; HVR-L1 comprising an amino acid sequence selected from SEQ ID NOs: 345, 15, 468 to 478, 495 to 517, 522 to 534, 536 to 539, and 543 to 556; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 346; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 347;
b) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 72; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 73; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 74; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 75; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 76; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 77;
c) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 42; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 43; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 44; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 45; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 46; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 47;
d) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 62; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 63; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 64; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 65; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 66; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 67;
e) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 212; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 213; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 214; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 215; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 216; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 217;
f) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 32; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 33; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 34; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 35; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 36; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 37; or
g) HVR-H1 comprising the amino acid sequence of SEQ ID NO: 52; HVR-H2 comprising the amino acid sequence of SEQ ID NO: 53; HVR-H3 comprising the amino acid sequence of SEQ ID NO: 54; HVR-L1 comprising the amino acid sequence of SEQ ID NO: 55; HVR-L2 comprising the amino acid sequence of SEQ ID NO: 56; and HVR-L3 comprising the amino acid sequence of SEQ ID NO: 57.
US Pat. No. 10,340,150

NI:NIGE:GE SELECTIVE ETCH FORMULATIONS AND METHOD OF USING SAME

Entegris, Inc., Billeric...

1. A composition comprising about 0.01 wt % to about 10 wt % of at least one non-oxidizing acid, about 0.01 wt % to about 10 wt % of at least one unreacted metal dissolution agent, about 0.01 wt % to about 5 wt % of at least one germanium passivation agent, about 0.01 wt % to about 5 wt % of at least one metal germanide passivation agent, and about 70 wt % to about 99.96 wt % of at least one solvent,wherein the at least one non-oxidizing acid comprises a species selected from the group consisting of methanesulfonic acid, oxalic acid, citric acid, tartaric acid, picolinic acid, succinic acid, lactic acid, sulfosuccinic acid, benzoic acid, propionic acid, formic acid, oxalic acid, maleic acid, malonic acid, fumaric acid, malic acid, ascorbic acid, mandelic acid, heptanoic acid, butyric acid, valeric acid, glutaric acid, phthalic acid, hypophosphorous acid, 5-sulfosalicylic acid, hydrochloric acid, and combinations thereof, preferably oxalic acid, 5 sulfosalicylic acid, or combinations thereof;
wherein the unreacted metal dissolution agent comprises a species selected from the group consisting of ammonium sulfite monohydrate, ammonium sulfate, ammonium hypophosphite, tetrabutyl ammonium cyanate, sodium sulfite, potassium sulfite, sodium erythorbate, tocopherol, naringenin, glutathione, and combinations thereof;
wherein the germanium passivation agent comprises a species selected from the group consisting of boric acid, ammonium biborate, ammonium pentaborate, sodium tetraborate, 3-hydroxy-2-naphthoic acid, malonic acid, alkyltrimethylammonium chloride, alkyltrimethylammonium bromide, decyltrimethylammonium chloride, carnitine, betaine, and combinations thereof;
wherein the metal germanide passivation agent comprises a species selected from the group consisting of 2-isopropylmalic acid, 2-propylmalic acid, 3-(4-hydroxyphenyl)lactic acid, 3-propylmalic acid, 4 hydroxymandelic acid, 2-hydroxyoctanoic acid, mandelic acid, squaric acid, 2-oxo-carboxylic acids, 5-sulfosalicylic acid, ethyl thioglycolate, 1,2-ethanedithiol, cysteine, methionine, dibenzothiophene, S-adenosylmethionine, taurine, glutathione, thiolactic acid, thiosalicylic acid, 2,2?-thiodiacetic acid, 3,3?-thiodipropionic acid, thioglycolic acid, dithiodiglycolic acid, 2,2?-(ethylenedithio)diacetic acid, 3-methoxybutyl thioglycolate, methyl thioglycolate, and combinations thereof and wherein the composition selectively removes unreacted metal relative to metal germanide, metal-III-V materials and germanium from the microelectronic device having the same thereon; and
wherein the solvent comprises a species selected from the group consisting of water, methanol, ethanol, isopropanol, butanol, pentanol, hexanol, 2-ethyl-1-hexanol, heptanol, octanol, and higher alcohols, 4-methyl-2-pentanol, ethylene glycol, propylene glycol, butylene glycol, butylene carbonate, ethylene carbonate, propylene carbonate, dipropylene glycol, diethylene glycol monomethyl ether, triethylene glycol monomethyl ether, diethylene glycol monoethyl ether, triethylene glycol monoethyl ether, ethylene glycol monopropyl ether, ethylene glycol monobutyl ether, diethylene glycol monobutyl ether, triethylene glycol monobutyl ether, ethylene glycol monohexyl ether, diethylene glycol monohexyl ether, ethylene glycol phenyl ether, propylene glycol methyl ether, tripropylene glycol methyl ether (TPGME), dipropylene glycol dimethyl ether, dipropylene glycol ethyl ether, propylene glycol n-propyl ether, dipropylene glycol n-propyl ether (DPGPE), tripropylene glycol n-propyl ether, propylene glycol n-butyl ether, dipropylene glycol n-butyl ether, tripropylene glycol n-butyl ether, propylene glycol phenyl ether, and combinations thereof.
US Pat. No. 10,336,820

ANTIBODIES DIRECTED TO ANGIOPOIETIN-1 AND ANGIOPOIETIN-2 AND USES THEREOF

Amgen Inc., Thousand Oak...

1. A method of treating a solid tumor in a subject, comprising administering to the subject an effective amount of an isolated monoclonal antibody to inhibit tumor-associated neovascularization, wherein said antibody comprises a heavy chain variable domain and a light chain variable domain, wherein said heavy chain comprises 3 CDRs and said light chain comprises 3 CDRs, wherein the sequences of said CDRs of said antibody are selected from the group consisting of:(a) SEQ ID NOs: 18, 26, 32 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(b) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(c) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 20, 27, 36 of the LC,
(d) SEQ ID NOs: 18, 26, 37 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(e) SEQ ID NOs: 18, 26, 38 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(f) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(g) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 21, 27, 33 of the LC,
(h) SEQ ID NOs: 18, 28, 39 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(i) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 22, 27, 33 of the LC,
(j) SEQ ID NOs: 18, 26, 32 of the HC plus SEQ ID NOs: 22, 27, 33 of the LC,
(k) SEQ ID NOs: 18, 29, 39 of the HC plus SEQ ID NOs: 19, 27, 33 of the LC,
(l) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 23, 27, 33 of the LC,
(m) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 20, 27, 40 of the LC,
(n) SEQ ID NOs: 18, 26, 32 of the HC plus SEQ ID NOs: 21, 27, 33 of the LC,
(o) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 24, 27, 33 of the LC,
(p) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 21, 27, 33 of the LC,
(q) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 23, 27, 33 of the LC,
(r) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 20, 30, 33 of the LC,
(s) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 25, 27, 33 of the LC,
(t) SEQ ID NOs: 18, 26, 35 of the HC plus SEQ ID NOs: 20, 30, 33 of the LC,
(u) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 20, 27, 40 of the LC, and
(v) SEQ ID NOs: 18, 26, 34 of the HC plus SEQ ID NOs: 20, 31, 33 of the LC;wherein said antibody specifically binds to at least one of Angiopoietins-1 (Ang-1) and Angiopoetin-2 (Ang-2) ligands of Tie 2 receptor tyrosine kinase.
US Pat. No. 10,336,822

EARLY MARKER OF PROTEINURIA IN PATIENTS TREATED WITH AN ANTI-VEGF TREATMENT

Mayo Foundation for Medic...

1. A method for treating a human having cancer, wherein said method comprises:(a) administering an original dose of an anti-VEGF therapy to said human to treat said cancer, and
(b) administering a subsequent dose of said anti-VEGF therapy to said human, wherein said human, following administration of said original dose, was identified as having a urine sample that lacks podocytes or polypeptides expressed by podocytes, wherein said subsequent dose is the same amount as said original dose.
US Pat. No. 10,334,772

GROWTH ENHANCEMENT OF PLANT

RHODIA OPERATIONS, Paris...

18. A seed coated by at least one cationic galactomannan selected from the group consisting of: cationic fenugreek gum, cationic tara gum, cationic locust bean gum, and cationic cassia gum, wherein the at least one cationic compound has an average Molecular Weight of from about 20,000 Daltons to 20,000,000 Daltons.
US Pat. No. 10,336,823

ANTI-B7-H1 ANTIBODIES FOR TREATING TUMORS

MedImmune Limited, Cambr...

1. A method of treating a patient identified as having non-small cell lung carcinoma (NSCLC), the method comprising administering to the patient 10 mg/kg of an isolated antibody or an antigen-binding fragment thereof that specifically binds to PD-L1, the isolated antibody or fragment thereof comprising:a VH CDR1 having the amino acid sequence of SEQ ID NO: 3;
a VH CDR2 having the amino acid sequence of SEQ ID NO: 4;
a VH CDR3 having the amino acid sequence of SEQ ID NO: 5;
a VL CDR1 having the amino acid sequence of SEQ ID NO: 6;
a VL CDR2 having the amino acid sequence of SEQ ID NO: 7; and
a VL CDR3 having the amino acid sequence of SEQ ID NO: 8,wherein at least 25% of the NSCLC tumor cells are PD-L1 positive.
US Pat. No. 10,337,079

MARAGING STEEL

DAIDO STEEL CO., LTD., N...

1. A maraging steel consisting of:as essential components,
0.20 mass %?C5.1?0.35 mass %,
9.0 mass %?Co?20.0 mass %,
1.0 mass %?(Mo+W/2)?2.0 mass %,
1.0 mass %?Cr?4.0 mass %, and
a certain amount of Ni, and
as optional components,
Al?0.10 mass %,
Ti?0.10 mass %,
S?0.0010 mass %,
N?0.0020 mass %,
V+Nb?0.60 mass %,
B?0.0050 mass %, and
Si?1.0 mass %,
with a balance being Fe and inevitable impurities,
wherein, in a case where contents of V and Nb satisfy V+Nb?0.020 mass %, an amount of Ni is:
6.0 mass %?Ni?9.4 mass %, and
wherein, in a case where the contents of V and Nb satisfy0.020 mass %
US Pat. No. 10,336,824

ANTI-PDL1 ANTIBODIES, ACTIVATABLE ANTI-PDL1 ANTIBODIES, AND METHODS OF THEREOF

CytomX Therapeutics, Inc....

1. An isolated antibody or antigen binding fragment thereof (AB) wherein the AB comprises:(a) a heavy chain variable region (VH) comprising:
i. a variable heavy chain complementarity determining region 1 (VH CDR1) comprising the amino acid sequence of SEQ ID NO: 2.12;
ii. a variable heavy chain complementarity determining region 2 (VH CDR2) comprising the amino acid sequence of SEQ ID NO: 246;
iii. a variable heavy chain complementarity determining region 3 (VH CDR3) comprising the amino acid sequence of SEQ ID NO: 235; and
(b) a light chain variable region (VL) comprising:
i. a variable light chain complementarity determining region 1 (VL CDR1) comprising the amino acid sequence of SEQ ID NO: 209;
ii. a variable light chain complementarity determining region 2 (VL CDR2) comprising an amino acid sequence of SEQ ID NOs: 215 or 227; and
iii. a variable light chain complementarity determining region 3 (VL CDR3) comprising the amino acid sequence of SEQ ID NO: 228,
wherein the AB specifically binds mammalian PDL1.
US Pat. No. 10,337,080

PROCESS FOR THE PRODUCTION OF GRAIN NON-ORIENTED ELECTRIC STEEL STRIP, WITH AN HIGH DEGREE OF COLD REDUCTION

CENTRO SVILUPPO MATERIALI...

1. A process for the production of a grain non-oriented electric steel strip, wherein the steel comprises by weight:Si 1.8%-6%
Al 0.2%-4%
Mn 0.2%-3%
S 0.0005%-0.01%
N 0.001%-0.01%
C 0.001%-0.01%
being Mn %/S %>100 and Al %/N %>200,
and, after casting and solidification in the form of a slab having a thickness Sp equal to or greater than 20 mm, is subjected to the following thermo-mechanical treatment:
optionally, heating of the slab at a temperature between 1000° C. and 1330° C.,
hot rolling of the slab to a temperature between 1300° C. and 700° C., with a total reduction rate between 70% and 99%, to obtain a hot rolled sheet (NAC) with thickness ranging between 2.5 mm and 12.0 mm,
cold rolling of the previously hot-rolled sheet, with a total reduction rate of not less than 80% according to the following sequence:
a) a first step of cold rolling (LAF) with a reduction rate between 20% and 70%, at a temperature below 300° C.;
b) an intermediate annealing softening at a temperature between 700° C. and 1100° C. for a time between 10 s and 900 s; and
c) a second step of cold rolling (LAF) with a reduction rate between 20% and 70%, wherein if said second step is repeated, it is preceded by an optional further intermediate annealing softening at a temperature between 700° C. and 1100° C. for a time between 10 [s] seconds and 900 [s] seconds,
final annealing for recrystallization and grains' growth, in continuous, of the cold-rolled sheet at a temperature between 800° C. and 1200° C. for a time of between 10 [s] seconds and 900 [s] seconds.
US Pat. No. 10,336,825

ANTIBODY BINDING TO FCRN FOR TREATING AUTOIMMUNE DISEASES

HANALL BIOPHARMA CO., LTD...

1. An isolated anti-FcRn antibody or an antigen-binding fragment thereof, comprising a heavy chain variable region comprising CDR1 comprising an amino acid sequence of SEQ ID No: 27, CDR2 comprising an amino acid sequence of SEQ ID No: 28, and CDR3 comprising an amino acid sequence of SEQ ID No: 29; and a light chain variable region comprising CDR1 comprising an amino acid sequence of SEQ ID No: 30, CDR2 comprising an amino acid sequence of SEQ ID No: 31, and CDR3 comprising an amino acid sequence of SEQ ID No: 32,wherein the antibody or antigen-binding fragment binds to an epitope of human FcRn comprising residues S15, S16, P17, P19, G20, A23, F24, S40, L41, R42, R69, E72, K73, F75, L76, F79, G84 and Y88 of ? chain extracellular domain (SEQ ID NO:45) and E36 of ?2m chain (SEQ ID NO:46).
US Pat. No. 10,336,058

USE OF THIAZOLIDE COMPOUNDS FOR THE PREVENTION AND TREATMENT OF VIRAL DISEASES, CANCER AND DISEASES CAUSED BY INTRACELLULAR INFECTIONS

ROMARK LABORATORIES L.C.,...

1. A method of stimulating an immune response in a subject in need thereof, comprising administering to the subject a pharmaceutical composition comprising a therapeutically effective amount of a thiazolide compound, wherein the thiazolide compound is nitazoxanide, tizoxanide, a mixture nitazoxanide and tizoxanide, N-(5-chlorothiazol-2-yl)-2-hydroxybenzamide, or a salt, ester, or amide thereof.
US Pat. No. 10,336,826

ANTIBODIES TO VLA-1

Biogen MA Inc., Cambridg...

1. A method of treating a subject having psoriasis, comprising administering to the subject a composition comprising an anti-VLA-1 antibody or antigen binding fragment thereof, and a pharmaceutically acceptable carrier, wherein the antibody or antigen binding fragment thereof comprises light chain complementarity determining regions defined by amino acid residues 24 to 33, 49 to 55 and 88 to 96 of SEQ ID NO:1, and heavy chain complementarity determining regions defined by amino acid residues 31 to 35, 50 to 65 and 98 to 107 of SEQ ID NO:2.
US Pat. No. 10,336,827

COMPOSITIONS AND METHODS TO TREAT SOLID TUMORS

Wayne State University, ...

1. A method of inducing apoptosis of cells of an ovarian tumor in a subject in need thereof comprising administering a therapeutically effective amount of an anti-CD11b antibody and/or Abciximab to the subject, thereby inducing apoptosis of cells of the ovarian cancer solid tumor in the subject.
US Pat. No. 10,336,828

FUSION POLYNUCLEOTIDE CONTAINING MURINE CMV PROMOTER AND METHOD OF PREPARING A POLYPEPTIDE OF INTEREST USING THE SAME

SAMSUNG BIOEPIS CO., LTD....

1. A fusion polynucleotide comprising a murine CMV promoter and an intron, wherein the intron is linked to the 5?-end or 3?-end of the murine CMV promoter, wherein the murine CMV promoter consists of SEQ ID NO: 9, and wherein the intron is an immunoglobulin intron or a chimeric intron.
US Pat. No. 10,337,085

DIE CASTING ALUMINUM ALLOY AND PRODUCTION METHOD THEREOF, AND COMMUNICATIONS PRODUCT

Huawei Technologies Co., ...

1. A die casting aluminum alloy consisting of the following components in percentage by mass:13.5% to 14.0% of silicon;
0.1% to 0.9% of manganese;
0.1% to 1.0% of magnesium;
0.3% to 1.4% of iron; and
less than or equal to 0.2% of copper and greater than 0% copper, and
a balance being aluminum and inevitable impurities.
US Pat. No. 10,336,830

ANTIBODIES AGAINST HUMAN CSF-1R AND USES THEREOF

HOFFMANN-LA ROCHE INC., ...

1. An isolated nucleic acid encoding an antibody binding to CSF-1R, wherein the antibody comprises a heavy chain variable domain and a light chain variable domain, and wherein:a) the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2, and a CDR1 region of SEQ ID NO: 3, and the light chain variable domain comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO:5, and a CDR1 region of SEQ ID NO:6, or
b) the heavy chain variable domain comprises a CDR3 region of SEQ ID NO: 9, a CDR2 region of SEQ ID NO: 10, and a CDR1 region of SEQ ID NO: 11, and the light chain variable domain comprises a CDR3 region of SEQ ID NO: 12, a CDR2 region of SEQ ID NO: 13, and a CDR1 region of SEQ ID NO: 14.
US Pat. No. 10,337,086

CORRODIBLE DOWNHOLE ARTICLE

Magnesium Elektron Limite...

1. A corrodible downhole article comprising a magnesium alloy which comprises0.4-10 wt % of a corrosion promoting element Ni,
2-8 wt % Y,
0.1-15 wt % of at least one rare earth metal other than Y, and
0-1 wt % Zr,
wherein a balance is magnesium and incidental impurities,
wherein the corrodible downhole article has a corrosion rate of at least 643 mg/cm2/day in 15% KCl at 93° C. and a 0.2% proof strength of at least 50 MPa when tested using standard tensile test method ASTM B557-10.
US Pat. No. 10,336,831

USE OF ANTI-ENDOGLIN ANTIBODIES FOR TREATING OCULAR FIBROSIS

Tracon Pharmaceuticals, I...

1. A method of treating or inhibiting an ocular fibrosis in a subject in need thereof, comprising administering to the subject an antibody, or antigen-binding fragment thereof, that specifically binds to endoglin; whereby the ocular fibrosis is treated or inhibited.
US Pat. No. 10,336,832

METHODS OF INHIBITING PLASMA KALLIKREIN IN EDEMA PATIENT

Dyax Corp., Lexington, M...

1. A method of inhibiting plasma kallikrein in a subject, the method comprising:administering to a subject in need thereof an antibody that binds to the active form of human plasma kallikrein and does not bind human prekallikrein;
wherein the subject has edema; and wherein the antibody comprises a heavy chain immunoglobulin variable domain sequence comprising three complementarity determining regions (CDRs) from the heavy chain variable domain of an antibody selected from the group consisting of: M162-A04, M160-G12, M142-H08, X63-G06, X101-A01, X81-B01, X67-D03, X67-G04, X115-B07, X115-D05, X115-E09, X115-H06, X115-A03, X115-D01, X115-G04, M29-D09, M145-D11, M06-D09, M76-D01, and M35-G04, and a light chain immunoglobulin variable domain sequence comprising three CDRs from the light chain variable domain of the selected antibody.
US Pat. No. 10,336,833

CONJUGATED ANTI-CD38 ANTIBODIES

Takeda Pharmaceutical Com...

1. An isolated antibody that specifically binds human CD38 (SEQ ID NO:1) and cynomolgus CD38 (SEQ ID NO:2) comprising:a) a heavy chain variable region comprising:
i) a first CDR comprising SEQ ID NO:3;
ii) a second CDR comprising SEQ ID NO:4;
iii) a third CDR comprising SEQ ID NO:5; and
b) a light chain variable region comprising:
i) a first CDR comprising SEQ ID NO:6;
ii) a second CDR comprising SEQ ID NO:7;
iii) a third CDR comprising SEQ ID NO:8; and
c) a covalently attached drug moiety,wherein the heavy chain variable region comprises an amino acid sequence having an identity of at least 90% to SEQ ID NO:9 and the light chain variable region comprises an amino acid sequence having an identity of at least 90% to SEQ ID NO:10.
US Pat. No. 10,336,834

METHODS OF USING ANTI-PHOSPHOLIPASE D4 ANTIBODIES

SBI Biotech Co., Ltd., T...

1. A method for suppressing an activity of a plasmacytoid dendritic cell in a living organism, comprising administering to the living organism an antibody, or antigen-binding fragment thereof, that binds to human phospholipase D4 (PLD4) protein on the plasmacytoid dendritic cell and suppresses the activity of the plasmacytoid dendritic cell, wherein the activity of the plasmacytoid dendritic cell is production of interferon, survival, or production of interferon and survival, and wherein the antibody or antigen-binding fragment thereof comprises:a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:2, a heavy chain CDR2 set forth in SEQ ID NO:3, and a heavy chain CDR3 set forth in SEQ ID NO:4, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:5, a light chain CDR2 set forth in SEQ ID NO:6, and a light chain CDR3 set forth in SEQ ID NO:7;
a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:8, a heavy chain CDR2 set forth in SEQ ID NO:9, and a heavy chain CDR3 set forth in SEQ ID NO:10, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:11, a light chain CDR2 set forth in SEQ ID NO:12, and a light chain CDR3 set forth in SEQ ID NO:13;
a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:14, a heavy chain CDR2 set forth in SEQ ID NO:15, and a heavy chain CDR3 set forth in SEQ ID NO:16, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:17, a light chain CDR2 set forth in SEQ ID NO:18, and a light chain CDR3 set forth in SEQ ID NO:19;
a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:20, a heavy chain CDR2 set forth in SEQ ID NO:21, and a heavy chain CDR3 set forth in SEQ ID NO:22, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:23, a light chain CDR2 set forth in SEQ ID NO:24, and a light chain CDR3 set forth in SEQ ID NO:25;
a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:26, a heavy chain CDR2 set forth in SEQ ID NO:27, and a heavy chain CDR3 set forth in SEQ ID NO:28, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:29, a light chain CDR2 set forth in SEQ ID NO:30, and a light chain CDR3 set forth in SEQ ID NO:31;
a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:32, a heavy chain CDR2 set forth in SEQ ID NO:33, and a heavy chain CDR3 set forth in SEQ ID NO:34, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:35, a light chain CDR2 set forth in SEQ ID NO:36, and a light chain CDR3 set forth in SEQ ID NO:37; or
a heavy chain variable region comprising a heavy chain CDR1 set forth in SEQ ID NO:38, a heavy chain CDR2 set forth in SEQ ID NO:39, and a heavy chain CDR3 set forth in SEQ ID NO:40, and a light chain variable region comprising a light chain CDR1 set forth in SEQ ID NO:41, a light chain CDR2 set forth in SEQ ID NO:42, and a light chain CDR3 set forth in SEQ ID NO:43.
US Pat. No. 10,336,835

POLYMORPHS OF SUGAMMADEX AND PROCESS FOR PREPARATION OF SUGAMMADEX

FORMOSA LABORATORIES, INC...

1. A crystalline form of Suagmmadex sodium, characterized by an X-ray powder diffraction pattern having peaks at 6.7, 17.6, 7.2, 20.8 and 21.4 degrees 2-theta±0.2 degrees 2-theta.
US Pat. No. 10,337,091

HIGH HEAT RESISTANT STEEL WITH LOW NICKEL

Hyundai Motor Company, S...

1. A high heat resistant steel having enhanced castability consisting of:C from about 0.5 to 0.7 wt %,
Si from about 1.3 to 1.7 wt %,
Mn from about 0.6 to 1.0 wt %,
Ni from about 24.0 to 26.0 wt %,
Cr from about 18.0 to 20.0 wt %,
Nb from about 1.0 to 2.0 wt %,
N from about 0.15 to 0.20 wt %, and
the remainder of iron (Fe), and inevitable impurities, based on a total weight of the high heat resistant steel,
wherein a value of X/Y is 0.44 to 0.47;
the X is a value calculated by Equation 1;
X=Cr (wt %)+1.5×Si (wt %)+0.5×Nb (wt %)  [Equation 1]
the Y is a value calculated by Equation 2;
Y=Ni (wt %+0.5×Mn (wt %)+30×C (wt %)+30×N (wt %),  [Equation 2]
wherein the steel has 190 MPa or more of tensile strength at 900° C.
US Pat. No. 10,336,837

PROCESS FOR PRODUCING OLEFIN POLYMER AND OLEFIN POLYMER

MITSUI CHEMICALS, INC., ...

1. A 1-butene polymer which has a meso pentad fraction as measured by 13C-NMR of 98.0% to 99.8%, has a melting point (Tm) of 120 to 150° C., and has a molecular weight distribution (Mw/Mn) of 1.5 to 2.75.
US Pat. No. 10,337,094

HOT-DIP GALVANIZED STEEL SHEET AND PRODUCTION METHOD THEREFOR

JFE Steel Corporation, T...

1. A hot-dip galvanized steel sheet comprising a steel sheet having a composition containing 0.100% to 0.200% C, 0.50% or less Si, 0.60% or less Mn, 0.100% or less P, 0.0100% or less S, 0.010% to 0.100% Al, and 0.0100% or less N on a mass basis, the remainder comprising Fe and inevitable impurities, the steel sheet having a microstructure containing a ferrite phase having an area fraction of 60% to 79%, a pearlite phase having an area fraction of 20% to 30%, and a bainite phase having an area fraction of 1% to 5%, the area fraction of a cementite phase present in a grain of the ferrite phase being 1% or more and 5% or less, wherein the hot-dip galvanized steel sheet has an elongation of 35.6% or more, a tensile strength of 440 MPa to 490 MPa, and a stretch flangeability of 77% or more.
US Pat. No. 10,336,839

FARNESENE-BASED POLYMERS AND LIQUID OPTICALLY CLEAR ADHESIVE COMPOSITIONS INCORPORATING THE SAME

FINA TECHNOLOGY, INC., H...

1. A laminated screen assembly comprising a transparent layer adhered to a display and a cured adhesive between the transparent layer and the display, wherein the cured adhesive is obtained by curing a liquid optically clear adhesive composition comprising a polymer derived from monomers comprising farnesene, the polymer being obtained from a diol prepared by anionically polymerizing monomers comprising farnesene to provide an intermediate polymer having two living ends, quenching the two living ends by reacting the two living ends with an alkylene oxide and a protic source, and hydrogenating the diol, wherein hydroxyl groups of the diol have been further reacted to provide terminal ends functionalized with (meth)acrylate groups and wherein the polymer has a degree of unsaturation less than or equal to 50%.
US Pat. No. 10,336,843

ULTRA-HIGH MOLECULAR WEIGHT ETHYLENE-BASED COPOLYMER POWDER, AND MOLDED ARTICLE USING ULTRA-HIGH MOLECULAR WEIGHT ETHYLENE-BASED COPOLYMER POWDER

Asahi Kasei Kabushiki Kai...

1. An ultra-high molecular weight ethylene-based copolymer powder comprising:an ethylene unit and an ?-olefin unit having 3 or more and 8 or less carbon atoms as structural units,
wherein the ultra-high molecular weight ethylene-based copolymer powder has a viscosity-average molecular weight of 100,000 or more and 10,000,000 or less,
a content of the ?-olefin unit is 0.01 mol % or more and 0.10 mol % or less based on a total amount of the ethylene unit and the ?-olefin unit, and
in measurement with a differential scanning calorimeter under following conditions, an isothermal crystallization time is determined as a time from reaching 126° C. of Step A3 as a starting point (0 min) to giving an exothermic peak top due to crystallization and the isothermal crystallization time is 5 minutes or more (Conditions for measurement of isothermal crystallization time);
Step A1: holding at 50° C. for 1 minute and then an increase up to 180° C. at a temperature rise rate of 10° C./min,
Step A2: holding at 180° C. for 30 minutes and then a decrease down to 126° C. at a temperature drop rate of 80° C./min, and
Step A3: holding at 126° C.
US Pat. No. 10,334,793

MINERAL WOOL PRODUCT

Knauf Insulation, Vise (...

1. A method of retaining water at an installation selected from a green roof, a landscape, a sports facility, a golf course and an urban garden, the method comprising providing at the installation a mineral wool batt which has an average density of at least 20 kg/m3 and which comprises needled mineral wool fibres.
US Pat. No. 10,337,100

SPUTTERING TARGET COMPRISING NI—P ALLOY OR NI—PT—P ALLOY AND PRODUCTION METHOD THEREFOR

1. A method of producing a Ni—P alloy sputtering target, wherein a Ni—P alloy containing 15 to 17 wt % of P and remainder being Ni and unavoidable impurities is melted and atomized to prepare a Ni—P alloy atomized powder having an average grain size of 100 ?m or less, the Ni—P alloy atomized powder is mixed with a Ni atomized powder, and the obtained mixed powder is hot pressed to produce a sintered compact containing 1 to 10 at % of P and a remainder of Ni and unavoidable impurities.
US Pat. No. 10,336,845

LOW ETHYLENE AMORPHOUS PROPYLENE-ETHYLENE-DIENE TERPOLYMER COMPOSITIONS

ExxonMobil Chemical Paten...

1. A propylene-ethylene-diene terpolymer comprising from 2% to 25% by weight of ethylene, from 98% to 75% by weight propylene and from 1% to 21% by weight of a diene, wherein the terpolymer has a crystallinity of less than 3%, a melt flow rate (MFR) of less than 10 g/10 min, and a Tg by DSC of from ?2° C. to ?25° C., and wherein the terpolymer does not comprise isotactic polypropylene sequences.
US Pat. No. 10,336,847

VINYL CHLORIDE-BASED POLYMER, METHOD FOR PREPARING THE SAME, AND THERMOPLASTIC RESIN COMPOSITION CONTAINING THE SAME

LG CHEM, LTD., Seoul (KR...

1. A vinyl chloride-based polymer containing 0.001 parts by weight or more and less than 2 parts by weight of an unsaturated fatty acid ester on the basis of 100 parts by weight of the vinyl chloride-based polymer,wherein the vinyl chloride-based polymer comprises a vinyl chloride-based monomer and the unsaturated fatty acid ester,
wherein the vinyl chloride-based monomer is a vinyl chloride monomer alone, or a combination of a vinyl chloride monomer and a comonomer copolymerizable therewith,
wherein the comonomer is a vinyl-based monomer,
wherein the unsaturated fatty acid ester includes cis- and trans-isomers of the unsaturated fatty acid ester, and
wherein the weight ratio between the cis- and trans-isomers of the unsaturated fatty acid ester is 60:40 to 90:10.
US Pat. No. 10,334,797

MELON PLANTS WITH A DOMINANT MELON YELLOWING ASSOCIATED VIRUS (MYAV) RESISTANCE GENE

NUNHEMS B.V., Nunhem (NL...

1. A non-wild cultivated Cucumis melo plant, or part thereof, comprising resistance against Melon Yellowing associated Virus (MYaV) wherein said resistance is conferred by an introgression fragment on chromosome 6 in homozygous or heterozygous form and wherein said introgression fragment is from a wild accession of the species Cucumis melo, a representative sample of seeds of said wild accession having been deposited under accession number NCI MB 41967 or NCIMB 41968, wherein said introgression fragment comprises at least two of the following SNP markers:a) the CC or AC genotype for the Single Nucleotide Polymorphism marker mME15090 in SEQ ID NO: 1;
b) the AA or AG genotype for the Single Nucleotide Polymorphism marker mME12135 in SEQ ID NO: 3;
c) the AA or AG genotype for the Single Nucleotide Polymorphism marker mME21377 in SEQ ID NO: 8; and/or
d) the TT or CT genotype for the Single Nucleotide Polymorphism marker mME13585 in SEQ ID NO: 12.
US Pat. No. 10,334,798

MELON VARIETY NUN 16215 MEM

NUNHEMS B.V., Nunhem (NL...

1. A plant, plant part or seed of melon variety NUN 16215 MEM, wherein a representative sample of seed of said melon variety is deposited under Accession Number NCIMB 43373.
US Pat. No. 10,336,849

COPOLYMER COMPRISING OXAZOLINE MONOMERS AND USE THEREOF AS CROSSLINKER

BASF SE, Ludwigshafen (D...

1. A copolymer A, comprising:at least one monomer (a) selected from the group consisting of a C1-20-alkyl (meth)acrylate, a C8-20-vinylaromatic, and a combination thereof;
at least one ethylenically unsaturated monomer (b), which comprises at least one sulfonic acid group (—SO3M), wherein M is one or more metals;
at least one ethylenically unsaturated monomer (c), which comprises at least one oxazoline group;
and optionally at least one further monomer (d) and/or additive,
wherein a fraction of the monomers (b) and (c) is in total less than 50% by weight, based on the total amount of the monomers in the copolymer A, and
wherein the copolymer A is a water-soluble polymer having a solubility in water of at least 100 g/l.
US Pat. No. 10,340,437

THERMOELECTRIC DEVICES

XILICO, LLC, Thousand Oa...

1. A method of fabricating a thermoelectric device, comprising:a. operatively connecting a first set of interconnects with respective p-type legs to form an array of p-type components, the first set of interconnects comprising a plurality of interconnects, each interconnect comprising a first end and a second end opposite the first end, each p-type leg comprising a proximal end and a distal end, wherein the proximal end of each p-type leg is operatively connected to the first end of the respective interconnect of the first set of interconnects;
b. operatively connecting a second set of interconnects with respective n-type legs to form an array of n-type components, the second set of interconnects comprising a plurality of interconnects, each interconnect comprising a first end and a second end opposite the first end, each n-type leg comprising a proximal end and a distal end, wherein the proximal end of each n-type leg is operatively connected to the first end of the respective interconnect of the second set of interconnects;
c. operatively connecting the array of p-type components to a first non-conducting substrate;
d. operatively connecting the array of n-type components to a second non-conducting substrate; and
e. assembling the array of p-type components with the array of n-type components to form a thermoelectric generator wherein the distal ends of the p-type legs are directly connected to a respective second end of the second set of interconnects, and the distal ends of the n-type legs are directly connected to a respective second end of the first set of interconnects to form a thermoelectric generator.
US Pat. No. 10,334,799

HYBRID TOMATO VARIETY H1765

H.J. Heinz Company Brands...

1. Tomato seed designated as ‘H1765’, representative sample of seed having been deposited under ATCC Accession Number PTA-124675.
US Pat. No. 10,334,800

VARIETY CORN LINE KID4330

Syngenta Participations A...

1. A seed of maize variety KID4330, wherein representative seed of said maize variety KID4330 has been deposited under ATCC Accession Number PTA-124542.
US Pat. No. 10,334,801

SOYBEAN VARIETY SM14328903

Agrigenetics, Inc., Indi...

1. A seed of soybean variety SM14328903, wherein a representative sample of the seed having been deposited under ATCC Accession No. PTA-123575.
US Pat. No. 10,334,802

MAIZE HYBRID X00M487

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X00M487, representative seed produced by crossing a first plant of variety PH42WT with a second plant of variety PH1W4R, wherein representative seed of the varieties PH42WT and PH1W4R have been deposited under ATCC Accession Numbers PTA-124778 and PTA-121351, respectively.
US Pat. No. 10,336,853

POLYMER, PROCESS AND COMPOSITION

DSM IP ASSETS B.V., Heer...

1. A process for preparing a copolymer having a low molecular weight and high glass transition temperature, wherein the process comprises conducting a solution polymerisation process of a monomer composition comprising:(a) from 20 to 80 wt-% of at least one itaconate functional monomer not containing acidic groups or precursor acid groups,
(b) not more than 40 wt-% of an acid functional monomer in an amount sufficient to achieve an acid value from 160 to 325 mg KOH per g of solid copolymer, and
(c) optionally not more than 72 wt. % of monomers other than monomers (a) or (b); wherein
the weight percentages of monomers (a), (b) and (c) total 100% and are calculated as a proportion of the total amount of monomers in the copolymer being 100%; and with the provisos:
(I) the copolymer has a number average molecular weight (Mn) of no more than 15 kilograms per mole; and
(II) the copolymer has a glass transition temperature of at least 75° C., and
(III) the copolymer contains less than 40 wt-% vinyl aromatic monomer; and optionally
(IV) the copolymer contains less than 40 wt-% methacrylate monomer.
US Pat. No. 10,334,803

MAIZE HYBRID X95M224

PIONEER HI-BRED INTERNATI...

1. A seed of hybrid maize variety X95M224, representative seed produced by crossing a first plant of variety PH259Y with a second plant of variety PH2RRS, wherein representative seed of the varieties PH259Y and PH2RRS have been deposited under ATCC Accession Numbers PTA-122443 and PTA-124303, respectively.
US Pat. No. 10,336,854

ALKOXYSILANE-FUNCTIONALIZED AND ALLOPHANATE-FUNCTIONALIZED URETHANES

Evonik Degussa GmbH, Ess...

1. An alkoxysilane-functionalized and allophanate-functionalized urethane comprising the reaction product ofat least one alkoxysilane group-containing monourethane A) of formula 1
Rn(OR1)3-nSi—R2—NH—(C?O)—OR3  formula 1
where Rn, R1, and R3 are each independently hydrocarbyl radicals having 1-8 carbon atoms, which may be linear, branched or cyclic, or else may be integrated together to form a cyclic system, and n is 0-2,
R2 is a diradical having 1-8 carbon atoms, which may be linear, branched or cyclic, or else may be integrated together to form a cyclic system,
and
at least one diisocyanate B),
in a molar ratio of A) to B) of from 1.0:1.5 to 1.0:0.6,
optionally in the presence of at least one catalyst K),
and the subsequent the at least one reaction product
with at least one diol and/or polyol C),
optionally in the presence of at least one catalyst K),
in the ratio of the NCO groups of the at least one reaction product to the OH groups of the diol and/or polyol C of from 1.0:1.5 to 1.0:0.6.
US Pat. No. 10,337,110

DEVICE AND METHOD FOR THE FLEXIBLE USE OF ELECTRICITY

Covestro Deutschland AG, ...

1. A method for flexible use of electrical power, wherein chlorine is produced by chlor-alkali electrolysis in a device comprising an electrolysis cell for chlor-alkali electrolysis having an anode half-cell, a cathode half-cell and a cation exchange membrane that separates the anode half-cell and the cathode half-cell from one another, an anode arranged in the anode half-cell for evolution of chlorine, an oxygen-consuming electrode arranged in the cathode half-cell as cathode, and a conduit for supply of gaseous oxygen to the cathode half-cell, wherein the device has at least one conduit for purging of the cathode half-cell with inert gas and wherein:a) when power supply is low, the oxygen-consuming electrode is supplied with gaseous oxygen, and oxygen is reduced at the oxygen-consuming electrode at a first cell voltage; and
b) when power supply is high, the oxygen-consuming electrode is not supplied with oxygen, and hydrogen is generated at the cathode at a second cell voltage which is higher than the first cell voltage.
US Pat. No. 10,334,804

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH464053

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH464053, produced by crossing a first plant of variety CV691450 with a second plant of variety CV759867, wherein representative seeds of said varieties CV691450 and CV759867 are deposited under ATCC Accession Nos. PTA-125241 and PTA-124497, respectively.
US Pat. No. 10,336,855

AQUEOUS PEPTIDE-FUNCTIONALIZED POLYURETHANE DISPERSIONS

Max-Planck-Gesellschaft Z...

1. A process for manufacturing a peptide-functionalized polyurethane dispersion (PUD), comprising:(1) providing an NCO-terminated polyurethane prepolymer;
(2) reacting said NCO-terminated polyurethane prepolymer with a compound comprising at least one NCO-reactive group and at least one maleimide group to obtain a maleimide-terminated polyurethane prepolymer;
(3) dispersing said maleimide-terminated polyurethane prepolymer into a continuous aqueous phase; and
(4) reacting the maleimide-terminated polyurethane prepolymer with one or more peptides, wherein said one or more peptides comprise amino acid side chains reactive with the maleimide group, thereby forming peptide-functionalized polyurethane particles.
US Pat. No. 10,334,805

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH818252

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH818252, produced by crossing a first plant of variety CV730108 with a second plant of variety CV644326, wherein representative seeds of said varieties CV730108 and CV644326 are deposited under ATCC Accession Nos. PTA-124485 and PTA-125218, respectively.
US Pat. No. 10,336,856

ALKOXYSILANE- AND ALLOPHANATE-FUNCTIONALIZED COATING MATERIALS

Evonik Degussa GmbH, Ess...

1. An alkoxysilane-functionalized and allophanate-functionalized coating material comprisinga) a binder component of 10-99 wt % of at least one reaction product of
one an alkoxysilane-containing monourethane A) of formula 1
Rn(OR1)3-nSi—R2—NH—(C?O)—OR3  formula 1
wherein R, R1, and R3 independently of one another represent hydrocarbon radicals, and R2 is a diradical, having 1-8 carbon atoms, wherein these may be linear, branched or cyclic or else may be integrated together to form a cyclic system, and n represents 0-2, and
a diisocyanate B),
optionally in the presence of at least one catalyst K),
in a molar ratio of A) to B) of from 1.0:1.5 to 1.0:0.6,
II,
and subsequent reaction of the at least one reaction product
with at least one diol and/or polyol C),
in the presence of at least one catalyst K),
in a ratio of NCO groups of reaction product to OH groups of the diol and/or polyol C) of from 1.0:1.5 to 1.0:0.6;
b) from 1-90 wt % of a hydroxyl-containing or amino-containing binder component,
c) from 0-50 wt % of at least one aromatic, aliphatic or cycloaliphatic polyisocyanate having an NCO functionality of at least 2,
d) from 0-5 wt % of at least one catalyst,
wherein a)-d) add up to 100 wt %,
e) optionally auxiliaries and/or additives,
f) optionally solvents.
US Pat. No. 10,334,806

LETTUCE VARIETY NUN 06773 LTL

NUNHEMS B.V., Nunhem (NL...

1. A plant or plant part of lettuce variety NUN 06773LTL, wherein a representative sample of said seed has been deposited under Accession Number NCIMB 42769.
US Pat. No. 10,334,807

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH288822

MONSANTO TECHNOLOGY LLC, ...

1. A seed of hybrid corn variety CH288822, produced by crossing a first plant of variety CV181138 with a second plant of variety CV844429, wherein representative seeds of said varieties CV181138 and CV844429 are deposited under ATCC Accession Nos. PTA-123825 and PTA-121106, respectively.
US Pat. No. 10,334,808

PLANTS AND SEEDS OF HYBRID CORN VARIETY CH181639

Monsanto Technology LLC, ...

1. A seed of hybrid corn variety CH181639, produced by crossing a first plant of variety CV595836 with a second plant of variety CV093813, wherein representative seeds of said varieties CV595836 and CV093813 are deposited under ATCC Accession Nos. PTA-PTA-125248 and PTA-123818, respectively.
US Pat. No. 10,336,859

METHOD FOR PREPARING AN ELECTROLYTE CAPACITOR

TAYCA CORPORATION, Osaka...

1. A method for preparing an electrolyte capacitor, comprising:providing an oxidant dopant agent for preparing a conductive polymer comprising:
ferric naphthalenesulfonate; and
at least one compound selected from the group consisting of phosphate, phosphite, borate, thiophosphate, and dithiophosphate:
providing a capacitor element;
providing a monomer;
applying the monomer and the oxidant dopant agent on the capacitor element and polymerizing to obtain a conductive polymer on the capacitor element;
providing an exterior material outside the conductive polymer, wherein the conductive polymer serves as an electrolyte of the electrolyte capacitor.
US Pat. No. 10,334,809

SOYBEAN VARIETY AM10995412

Agrigenetics, Inc., Indi...

1. A seed of soybean variety AM10995412, wherein a representative sample of the seed having been deposited under ATCC Accession No. PTA-125666.
US Pat. No. 10,334,810

SOYBEAN VARIETY MN11277371

Agrigenetics, Inc., Indi...

1. A seed of soybean variety MN11277371, wherein a representative sample of the seed having been deposited under ATCC Accession No. PTA-123684.
US Pat. No. 10,336,861

PHOSPHORUS-CONTAINING CAPROLACTONE MONOMERS FOR SYNTHESIS OF FLAME RETARDANT POLYCAPROLACTONES

International Business Ma...

1. A flame retardant polycaprolactone formed according to a process comprising:utilizing a caprolactone molecule to form a hydroxyl-functionalized caprolactone molecule;
chemically reacting the hydroxyl-functionalized caprolactone molecule with a phosphorus-containing flame retardant molecule to form a flame retardant-functionalized caprolactone monomer, wherein the phosphorus-containing flame retardant molecule includes an allyl group, an epoxide group, or a furan group; and
polymerizing a mixture that includes at least the flame retardant-functionalized caprolactone monomer to form a flame retardant polycaprolactone.
US Pat. No. 10,334,811

SOYBEAN VARIETY 5PQBB44

PIONEER HI-BRED INTERNATI...

1. A plant or a seed of soybean variety 5PQBB44, representative seed of the variety having been deposited under ATCC Accession Number PTA-125282.
US Pat. No. 10,334,812

ALFALFA VARIETY RRL913T404

Forage Genetics Internati...

1. A seed of alfalfa variety RRL913T404, wherein representative seed of said alfalfa variety have been deposited under ATCC Accession No. PTA-125618.
US Pat. No. 10,334,813

BEAN VARIETY SVGA4608

Seminis Vegetable Seeds, ...

1. A bean plant of bean line SVGA4608, a sample of seed of the line having been deposited under ATCC Accession Number PTA-124713.
US Pat. No. 10,337,376

EXHAUST GAS PURIFICATION SYSTEM FOR AN INTERNAL COMBUSTION ENGINE

Toyota Jidosha Kabushiki ...

1. An exhaust gas purification system for an internal combustion engine, comprising:a first fuel supply unit configured to supply fuel to exhaust gas flowing through an exhaust passage of the internal combustion engine with a supply valve arranged in the exhaust passage;
a second fuel supply unit configured to supply fuel to exhaust gas to be discharged to the exhaust passage by adjusting a fuel injection condition for the internal combustion engine;
an oxidation catalyst arranged in the exhaust passage on a downstream side of the supply valve;
a calculation unit configured to calculate a concentration of fuel in the exhaust gas flowing into an NOx selective catalytic reduction catalyst;
a threshold obtaining unit configured to obtain, based on the temperature of the NOx selective catalytic reduction catalyst, a predetermined fuel concentration threshold;
an exhaust gas purification device arranged in the exhaust passage on a downstream side of the oxidation catalyst, the exhaust gas purification device comprising an exhaust gas purification element and the NOx selective catalytic reduction catalyst; and
a temperature rise control unit configured to carry out temperature raising processing which raises a temperature of exhaust gas flowing into the exhaust gas purification device by supplying fuel to the exhaust gas and oxidizing the supplied fuel in the oxidation catalyst, in order to raise a temperature of the exhaust gas purification element to a predetermined target temperature,
wherein, in the temperature raising processing, the temperature rise control unit is configured to:
raise the temperature of the exhaust gas purification element to the predetermined target temperature by performing first control in which fuel supply by the first fuel supply unit is carried out;
maintain the exhaust gas purification element at the predetermined target temperature by performing at least second control in which a ratio of an amount of fuel supply by the second fuel supply unit with respect to an amount of fuel supply by the first fuel supply unit becomes higher in comparison with that when performing the first control;
when the temperature of the NOx selective catalytic reduction catalyst exceeds a predetermined temperature threshold and the fuel concentration calculated by the calculation unit does not exceed the predetermined fuel concentration threshold, maintain the exhaust gas purification element at the predetermined target temperature by performing the first control, without performing the second control; and
when the temperature of the NOx selective catalytic reduction catalyst exceeds the predetermined temperature threshold and the fuel concentration calculated by the calculation unit exceeds the predetermined fuel concentration threshold, maintain the exhaust gas purification element at the predetermined target temperature by performing the second control.
US Pat. No. 10,334,814

PEA VARIETY SV5685QG

Seminis Vegetable Seeds, ...

1. A pea plant of pea line SV5685QG, a sample of seed of the line having been deposited under ATCC Accession Number PTA-124985.
US Pat. No. 10,335,841

METHOD OF FORMING AN AL—MG ALLOY PLATE PRODUCT

ALERIS ROLLED PRODUCTS GE...

1. A method of obtaining a predetermined two- or three-dimensional formed structure of an AlMg alloy plate product, comprising the steps of:providing an alloy plate having a gauge of at least 10 mm and a chemical composition, in wt. %:
Mg 2.5% to 6%,
Mn 0 to 1.2%,
Sc 0 to 1%,
Ag 0 to 0.5%,
Zn 0 to 2%,
Cu 0 to 2%,
Li 0 to 3%,
optionally at least one or more elements selected from the group consisting of Zr 0.03% to 0.4%, Cr 0.03% to 0.4%, and Ti 0.005% to 0.3%,
optionally one or more elements selected from the group of Er, Dy, Gd, and Hf in a total amount of 0.03% to 0.3%,
Fe 0 to 0.4%,
Si 0 to 0.25%,
inevitable impurities and balance aluminium;
shaping or forming the alloy plate at a temperature in a range of 200° C. to 400° C. to obtain the predetermined two- or three-dimensional formed structure; and
heat treating the predetermined two- or three-dimensional formed structure.
US Pat. No. 10,336,866

METHOD FOR PRODUCING ORGANOSILICON COMPOUNDS HAVING AMINO GROUPS

Wacker Chemie AG, Munich...

1. A method for producing aminofunctional polyorganosiloxanes of general formula I(SiO4/2)k(R1SiO3/2)m(R12SiO2/2)p(R13SiO1/2)q[O1/2SiR12—R—NR2R3]s[O1/2H]t  (I),
which comprises reacting
(A) organosiloxanes which contain Si—OH groups, of general formula (II)
(SiO4/2)k(R1SiO3/2)m(R12SiO2/2)p(R13SiO1/2)q[O1/2H]r  (II),with(B) at least a stoichiometric amount of a monoalkoxy(aminoalkyl)silane, based on the Si—OH groups, of general formula (III)
R2R3N—R—SiR12(OR4)  (III),
while utilizing less than 0.01 ppm of acid, less than 30 ppm of base and less than 0.4% of organometallic compound, wherein
R is an unsubstituted or halogen-substituted alkylene radical of 2 to 12 carbon atoms,
Rx is hydrogen, an unsubstituted C1-C10 hydrocarbyl radical or a C1-C10 hydrocarbyl radical substituted with substituents selected from —CN and halogen,
R1 is a hydrogen atom or a C1-C20 hydrocarbyl or C1-C15 hydrocarbyloxy radical which is bonded Si—C and is unsubstituted or substituted with substituents selected from —CN, NRx2, COOH, COORx, -halogen, -acryloyl, -epoxy, —SH, —OH and —CONRx2 and in each of which one or more mutually nonadjacent methylene units at a time may be replaced by groups —O—, —CO—, —COO—, —OCO— or —OCOO—, —S—, or NRx and in each of which one or more mutually nonadjacent methine units may be replaced by groups —N?, —N?N—, or —P?,
R2 and R3 are each hydrogen or unbranched, branched or cyclic saturated or unsaturated alkyl of 1 to 12 carbon atoms or aryl or aralkyl where individual nonadjacent methylene units may be replaced by nitrogen atoms or oxygen atoms,
R4 is linear or branched alkyl of 1 to 8 carbon atoms where nonadjacent methylene units may be replaced by oxygens,
s is not less than 1,
r is not less than 1,
s+t is equal to the value of r, and
k+m+p+q is not less than 2,
and s:t is not less than 10.
US Pat. No. 10,336,869

CARBON FIBER-REINFORCED RESIN COMPOSITION AND SHAPED PRODUCT OBTAINED THEREFROM

MITSUI CHEMICALS, INC., ...

1. A carbon fiber-reinforced resin composition, comprising:100 parts by mass of a polymer alloy (A) which comprises:
25 to 95% by mass of one or more propylene-based polymers (p) selected from a propylene-ethylene block copolymer, a propylene homopolymer and a propylene-ethylene random copolymer having an ethylene content of 5% by mass or less,
1 to 60% by mass of an acid-modified polyolefin resin (m),
0 to 40% by mass of an ethylene-based polymer (e) and
0 to 50% by mass of a polyamide (n)
wherein the total of the component (p), the component (m), the component (e) and the component (n) is 100% by mass, and
1 to 200 parts by mass of a carbon fiber (B);
the acid-modified polyolefin resin (m) comprises a maleic acid-modified propylene-based polymer (m1);
the total of Wp and Wm1 is 50 to 98% by mass, in which the content of the component (p) is expressed by Wp % by mass, the content of the component (m1) is expressed by Wm1% by mass (the content of the whole component (m) is expressed by Wm % by mass), the content of the component (e) is expressed by We % by mass, and the content of the component (n) is expressed by Wn % by mass in the polymer alloy (A), and the total of Wp, Wm, We and Wn is 100% by mass; and additionally; and,
the following formula (1):
QP×log(MFRP)+Qml×log(MFRml)>log 120  (1)
wherein, QP=WP/(WP+Wml), Qml=Wml/(WP+Wml)is satisfied in which the melt flow rate (MFR) of the component (p) measured at 230° C. under a load of 2.16 kg according to ASTM D1238 is expressed by MFRp (g/10 min) and the melt flow rate (MFR) of the component (m1) measured at 230° C. under a load of 2.16 kg according to ASTM D1238 is expressed by MFRm1 (g/10 min); and,wherein the melt flow rate MFR of the polymer alloy (A), measured at 230° C. under a load of 2.16 kg according to ASTM D1238, is 30 to 500 g/10 min.
US Pat. No. 10,336,870

GLASS FIBER SIZING COMPOSITIONS, SIZED GLASS FIBERS, AND POLYOLEFIN COMPOSITES

Telene SAS, Bondues (FR)...

1. A polyolefin composite, comprising:a plurality of glass fibers at least partially coated with a sizing composition comprising a silane and a film-former comprising a polymer, wherein the repeating unit of the polymer comprises at least four carbon atoms and at least one carbon-carbon double bond; and
a polyolefin prepared by combining (a) a cyclic olefin; (b) a metathesis catalyst for polymerizing the cyclic olefin; (c) 0.1-30 wt. % of a compound comprising at least one vinyl group; and (d) 0.1-10 wt. % of a curing agent for compound (c) to form a curable composition, and subjecting the curable composition to conditions effective to promote an olefin metathesis reaction of the cyclic olefin and a radical polymerization of compound (c).
US Pat. No. 10,337,129

PROCESS OF DEBUNDLING CARBON FIBER TOW AND MOLDING COMPOSITIONS CONTAINING SUCH FIBERS

Continental Structural Pl...

1. An article comprising:an inner layer of cured sheet molding composition having an inner layer thickness and comprising a thermoset resin matrix reinforced predominantly with dispersed, chopped carbon fibers;
an outer skin of a second cured sheet molding composition having an outer skin thickness and comprising a thermoset resin matrix reinforced predominantly with chopped glass fibers, wherein said outer skin is devoid of chopped carbon fiber, and wherein the outer skin is in contact with and joined to the inner layer; and
a ratio of the inner layer thickness to outer skin thickness between 0.1-10:1.
US Pat. No. 10,340,461

COMPOSITION FOR FORMING HOLE COLLECTING LAYER OF PHOTOSENSOR ELEMENT, AND PHOTOSENSOR ELEMENT

NISSAN CHEMICAL INDUSTRIE...

1. A photosensor element comprising an anode layer, a hole-collecting layer provided so as to be in contact with the anode layer, and a photoelectric conversion layer provided so as to be in contact with the hole-collecting layer,wherein the hole-collecting layer made from the photosensor element hole-collecting layer-forming composition comprises a charge-transporting substance having a molecular weight of from 200 to 2,000 and an organic solvent.
US Pat. No. 10,335,081

APPARATUS AND METHOD FOR INTERFACING TIME-VARIANT SIGNALS

United States GTM Medical...

1. A method of determining a status of an electrical connection between a monitoring device and a sensing device utilizing an interface circuit, said interface circuit configured for signal communication with each of said monitoring device and said sensing device, said method comprising:detecting, via said interface circuit, an excitation signal, said excitation signal provided by said monitoring device to said sensing device during operation of said sensing device and said monitoring device;
buffering, via said interface circuit, said excitation signal to produce a buffered excitation signal;
analyzing, via said interface circuit, said buffered excitation signal to identify variations therein indicative of said status of said electrical connection;
generating, via said sensing device, a binary digital signal representative of a time variant waveform; and
based at least in part on said status of said electrical connection indicating an established electrical connection between said monitoring device and said sensing device, generating an output signal derived at least in part from said binary digital signal, said output signal being compatible with and configured for delivery to said monitoring device;
wherein said derivation of said output signal is independent of said excitation signal.
US Pat. No. 10,336,876

ELONGATED GAS BARRIER LAMINATE AND METHOD FOR PRODUCING SAME

LINTEC CORPORATION, Toky...

1. A long gas barrier laminate including a functional layer, a base, a smoothing layer, and a gas barrier layer sequentially stacked,the functional layer being a hard coat layer or an anti-glare hard coat layer that is formed of cured product of an activated energy ray-curable resin composition including fine particles having an average size of 2 to 3 ?m,
the content of the fine particles in the activated energy ray-curable resin composition being 0.1 to 4.8 mass %,
the functional layer being stacked on one side of the base,
the smoothing layer and the gas barrier layer being sequentially stacked on the other side of the base,
a coefficient of static friction between a surface of the functional layer that is situated opposite to the base and a surface of the gas barrier layer that is situated opposite to the base being 0.35 to 0.80, and
a surface of the functional layer that is situated opposite to the base having a total height (Rt) of a roughness of 100 nm or more.
US Pat. No. 10,336,878

MICROCELLULAR FOAM EXTENSION DASH PANEL

FORD MOTOR COMPANY, Dear...

1. A method of molding a temperature resistant and sound attenuating part comprising:blending a foaming agent with a thermoplastic, basalt fibers and mica to form a resin mixture;
injecting the resin mixture into an injection mold at a pressure between 10,000 and 125 MPa;
holding the pressure in the mold until the mold is fully filled; and
reducing the pressure in the mold to a pressure of 7 MPa or less.
US Pat. No. 10,335,855

ADDITIVE MANUFACTURING OF FUNCTIONALLY GRADIENT DEGRADABLE TOOLS

BAKER HUGHES, A GE COMPAN...

1. An article comprising a plurality of micro-sized or nano-sized galvanic cells, wherein the article has a seamless structure encompassing a plurality of empty spaces of different sizes, geometries, distributions, or a combination thereof, and one or more of the following properties of the article vary in different directions: tensile strength; compressive strength; electrical resistance; thermal conductance; modulus; or hardness.
US Pat. No. 10,336,879

RIGID POLYURETHANE FOAM

ACHILLES CORPORATION, To...

1. A rigid polyurethane foam, which is obtained by mixing and reacting raw materials comprising a polyol, a polyisocyanate, a blowing agent, and a catalyst, whereinthe polyol comprises a polyester polyol having an aromatic concentration of 17 to 35% by weight, and a non-amine-based polyether polyol and/or aromatic amine-based polyether polyol,
the polyisocyanate is a mixture of MDI (diphenylmethane diisocyanate)/TDI (tolylene diisocyanate) in a weight ratio of 4/6 to 9/1,
the blowing agent comprises a halogenated olefin, and
the rigid polyurethane foam has a density of 33 to 60 kg/m3, a cell size of 230 ?m or less, and a thermal conductivity of 0.0190 W/(m·K) or less.
US Pat. No. 10,334,829

IMID SCREENING METHODS IMID-SENSITIVE CELLS WITH MUTANT CRBN

The Broad Institute, Inc....

5. A method of screening for an immunomodulatory imide drug (IMiD) that activates ubiquitin ligase, the method comprising:a) contacting an isolated mouse cell with an IMiD, wherein the genome of the cell comprises an exogenous polynucleotide encoding a mutant cereblon (CRBN) polypeptide at the endogenous CRBN locus, wherein said mutant CRBN comprises a point mutation selected from the group consisting of S369C, V380E, and I391V, and wherein the cell has IMiD sensitivity; and
b) detecting the amount of:
i) ubiquitination of IKAROS family zinc finger protein 1 (IKZF1) or IKAROS family zinc finger protein 3 (IKZF3);
ii) degradation of IKZF1 or IKZF3; or
iii) binding of CRBN to IKZF1 or IKZF3,
in the isolated cell obtained in step a);
wherein increased ubiquitination or degradation of IKZF1 or IKZF3 or increased binding of CRBN to IKZF1 or IKZF3 as compared to a wild-type isolated mouse cell indicates the IMiD activates ubiquitin ligase.
US Pat. No. 10,335,856

SYSTEM FOR TEMPERATURE CONTROLLED ADDITIVE MANUFACTURING

Applied Materials, Inc., ...

1. An additive manufacturing system, comprising:a platen having a top surface to support an object being manufactured;
a dispenser to deliver a plurality of successive layers of precursor material over the platen;
a plurality of lamps disposed below the top surface of the platen to heat the platen; and
an energy source to fuse at least some of the outermost layer of precursor material.
US Pat. No. 10,336,880

PROPYLENE RESIN FOAM PARTICLES AND FOAM PARTICLE MOLDED ARTICLE

JSP Corporation, Tokyo (...

1. An expanded propylene resin bead comprising a core layer being in a foamed state and constituted of a propylene-based resin composition (a) and a cover layer covering the core layer and constituted of an olefin-based resin (b),the propylene-based resin composition (a) satisfying the following (i) and (ii), and the olefin-based resin (b) satisfying the following (iii) or (iv):
(i) the propylene-based resin composition (a) is a mixture of 65% by weight to 98% by weight of a propylene-based resin (a1) having a melting point of 145° C. or more and less than 165° C. and a flexural modulus of 1,200 MPa or more and 35% by weight to 2% by weight of a propylene-based resin (a2) having a melting point of 135° C. to 145° C. and a flexural modulus of 1,000 MPa to 1,200 MPa, provided that a sum total weight of the propylene-based resin (a1) and the propylene-based resin (a2) is 100% by weight, wherein the propylene-based resin (a2) is obtained through polymerization in the presence of a metallocene-based polymerization catalyst;
(ii) a difference between the melting point of the propylene-based resin (a1) and the melting point of the propylene-based resin (a2) [(melting point of a1)?(melting point of a2)] is 5° C. to 25° C.;
(iii) the olefin-based resin (b) is a crystalline olefin-based resin having a melting point (TmB) that is lower than a melting point (TmA) of the propylene-based resin composition (a), with a difference between the melting point (TmA) and the melting point (TmB) [TmA?TmB] being more than 0° C. and 80° C. or less; and
(iv) the olefin-based resin (b) is a non-crystalline olefin-based resin having a softening point (TsB) that is lower than the melting point (TmA) of the propylene-based resin composition (a), with a difference between the melting point (TmA) and the softening point (TsB) [TmA?TsB] being more than 0° C. and 100° C. or less.
US Pat. No. 10,336,881

MONOLITHS

Alfred E. Mann Foundation...

1. A method of fabricating a self-wicking monolith for processing a fluid sample, the method comprising:providing at least one hydrophilic monomer and at least one linker monomer, the at least one linker monomer having two polymerizable groups spaced apart by a linker comprising at least one —C(R)2O— group; wherein each R is individually a hydrogen or an organic group;
optionally wherein at least one further monomer is provided;
obtaining a polymerizable composition by combining the at least one hydrophilic monomer and the at least one linker monomer in a porogenic solvent;
polymerising the polymerizable composition to form the self-wicking monolith;
obtaining the self-wicking monolith as a polymeric matrix free of the porogenic solvent and free of any unpolymerized monomers:
forming an amplification zone configured to facilitate amplification of a target nucleic acid sequences in the fluid sample;
forming a plurality of zones, wherein the zones have different wicking properties and/or chemical properties, and wherein the forming a plurality of zones comprises at least one of the following:
forming a clean-up zone configured to perform at least one of the following:
mechanical entrapment of a component in the fluid sample to retard or prevent movement of the component through a monolith during wicking;
affinity entrapment of a component in the fluid sample to retard or prevent movement of the component through a monolith during wicking;
facilitate one or more of polynucleotide release via disruption of somatic cells, viruses, bacteria, or fungi;
cytosol release through cell lysis; or
facilitate release of an analyte through disruption of masking effects in a sample matrix of the fluid sample;
forming a reverse transcription zone configured to facilitate reverse transcription of RNA to cDNA; or
forming an indication zone configured to facilitate detection of an analyte molecule, wherein the indication zone includes a dye fluorophore or a chromophore and optionally a quencher.
US Pat. No. 10,340,470

LIGHT-EMITTING ELEMENT, DISPLAY DEVICE, ELECTRONIC DEVICE, AND LIGHTING APPARATUS

Semiconductor Energy Labo...

1. A light-emitting element comprising:a cathode;
an anode;
a light-emitting layer;
a first layer;
a second layer; and
a third layer,
wherein the first layer is provided between the cathode and the light-emitting layer,
wherein the second layer is provided between the light-emitting layer and the third layer and comprises a region in contact with the third layer,
wherein the third layer is provided between the second layer and the anode and comprises a region in contact with the anode,
wherein the first layer comprises an alkali metal or an alkaline earth metal,
wherein the third layer comprises an alkali metal or an alkaline earth metal, and
wherein the second layer comprises a material having a function of transporting an electron.
US Pat. No. 10,336,883

COMPOSITIONS PREPARED USING AN IONIC CROSSLINKING AGENT AND METHODS OF MAKING THE SAME

BASF SE, Ludwigshafen (D...

1. An asphalt composition comprising:asphalt; aggregate; and
a crosslinked product prepared by ionically crosslinking a random copolymer derived from styrene and butadiene using an ionic crosslinking agent.
US Pat. No. 10,336,884

BLOCK COPOLYMERS FOR GEL COMPOSITIONS

Kraton Corporation, Hous...

1. A composition comprisingi) a hydrogenated styrenic block copolymer having a peak molecular weight of from 125 to 300 kg/mol, wherein said hydrogenated styrenic block copolymer is a diblock copolymer of formula S-EB;
wherein S is a polymer block of a monoalkenyl arene, and EB is a hydrogenated polymer block of 1,3-butadiene;
ii) an oil; and
iii) optionally one or more additives;
wherein the composition forms a gel having a thixotropic ratio at 25° C. of from 5 to 10.
US Pat. No. 10,337,140

METHOD OF MANUFACTURING A PENETRATION-RESISTANT ARTICLE THAT INCLUDES A TEXTILE FABRIC MADE FROM ARAMID FIBERS

TEIJIN ARAMID GMBH, Wupp...

1. A method of manufacturing a penetration-resistant article that comprises a textile fabric made from at least 80 wt. % of aramid fibers, the method comprising:a) finishing aramid fibers with finish solids comprising a carbonic acid polyester, wherein the carbonic acid polyester is produced by polycondensation of a carbonic acid ester or carbonic acid dichloride with one or more diols, and one chain end or both chain ends of the carbonic acid polyester comprises a hydroxyl group or an alkyl radical of a monovalent alcohol;
b) processing the finished aramid fibers into a textile fabric comprising the finished aramid fibers; and
c) processing the textile fabric into a penetration-resistant article, wherein the finish solids substantially remain on the finished aramid fibers throughout steps b) and c).
US Pat. No. 10,336,885

SAPONIFIED ETHYLENE-VINYL ESTER COPOLYMER COMPOSITION AND MULTILAYERED STRUCTURE USING SAID COMPOSITION

MITSUBISHI CHEMICAL CORPO...

1. A resin composition comprising (A) a saponified ethylene-vinyl ester copolymer and (B) a hydrate-formable alkaline earth metal salt,wherein the (B) hydrate-formable alkaline earth metal salt satisfies water absorption properties (I), (II), and (III):
(I) a ratio of X5/Y being in the range of 0.2 to 2.0 wherein the X5 is an amount of water absorption when (B) hydrate-formable alkaline earth metal salt is placed under a condition of 40 ° C. and 90% relative humidity for 5 days, and (Y) is a content of crystallization water in maximum hydrate of the (B) hydrate-formable alkaline earth metal salt;
(II) an amount of water absorption (Z) based on 100 g of (B) hydrate-formable alkaline earth metal salt being 10 g or more when the (B) hydrate-formable alkaline earth metal salt is placed under a condition of 40 ° C. and 90% relative humidity for 24 hours; and
(III) a local maximum point existing in change of amount of water absorption of the (B) hydrate-formable alkaline earth metal salt while placed under a high-temperature and high-humidity condition.
US Pat. No. 10,334,835

METHOD FOR PREPARING AN OPTIMUM DENSITY TERMITE BAIT COMPOSITION

BASF Corporation, Florha...

1. A composition in extruded form for use for termite monitoring and control, said composition comprising a cellulose material as a base bait and an active ingredient for at least one of killing and controlling termites, said composition being compacted to a density of not less than 1.033 g/cc.